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ABSTRACT
Breast cancer is the most common cancer in women worldwide, and is the second
leading cause of cancer-related death in spite of significant advances in treatment and
emphasis on early diagnosis. While treatment of localized disease is often successful,
metastatic breast cancer, especially of the triple negative molecular subtype, carries a
much poorer prognosis. The significant role of the immune system in the progression
from localized to metastatic disease is becoming more and more appreciated. Tumor
escape from immune surveillance and immune suppression in the tumor
microenvironment have become therapeutic targets in addition to the traditional goals of
directly killing tumor cells. A number of immune therapeutic strategies have been
proposed and tested, but few have seen clinical application in the treatment of breast
cancer. The development of successful breast cancer immunotherapeutic strategies
depends on the rapid identification of immunogenic antigens, timely delivery of these
antigens by the optimal vehicle to induce a robust immune response, and appropriate
combination with other therapies such as adjuvants, innate immune therapies, and the
current standard-of-care treatments. This will allow for more comprehensive targeting of
the breast cancer immune regulatory network and likely lead to improved therapeutic
success. In the following experiments, two immune therapies which address elements of
this multipronged approach will be investigated. The models in which these therapies are
tested for gross phenotypic effect are intended to bring basic murine models of
experimentation closer to the patterns of future clinical application. The first of these
iii

therapies is emodin, a natural, small molecule compound derived from several Chinese
herbs. Its immune modulatory properties have been demonstrated in a number of disease
models, but our lab was the first to show that it is capable of attenuating breast cancer
progression by blocking the interactions between tumor-associated macrophages and
cancer cells. Here emodin is tested as an adjuvant therapy following primary tumor
surgical removal for the purpose of preventing metastatic recurrence in a model of
murine triple negative breast cancer. We show that trough interfering with TGF-β1
signaling, emodin is capable of decreasing the ability of tumor cells to invade and
establish themselves at metastatic sites, thereby reducing metastatic recurrence and
increasing overall survival. In addition to its ability to disrupt the reciprocal signaling
between tumor cells and macrophages, emodin’s low cost and proven low toxicity make
it a promising innate immune therapy. The second therapeutic strategy focuses on
improving the effectiveness of dendritic cell-based therapeutic cancer vaccines. Our lab
was the first to reveal the role of microRNA-155 (miR155) as a key regulator of dendritic
cell function. Our previous work has shown that total-body knockout of miR155
increased both tumor growth and metastasis in an orthotopic model of murine breast
cancer. Our therapeutic goal is to increase the presence of miR155 in the immune cells of
the tumor microenvironment, most importantly in dendritic cells. Here, total immune
system overexpression of miR155 and a miR155-overexpressed DC vaccination therapy
are shown to reduce breast tumor growth and metastasis by boosting cytotoxic T cell
activity through it multiple positive effects on dendritic cell maturation and migration to
tumor-draining lymph nodes. From the results detailed here, both of these strategies hold
promise as valuable elements of future combination immune therapies for breast cancer.
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CHAPTER 1
INTRODUCTION
1.1 BREAST CANCER
The most prevalent non-skin malignancy worldwide is breast cancer. Though
second to lung cancer in terms of mortality, its much higher prevalence makes it the most
expensive malignancy to treat [1]. The annual cost is expected to rise to $20.5 billion by
2020 [2]. 12.3% of women will be diagnosed with breast cancer at some point in their
lives, and metastatic breast cancer remains largely incurable even with recent therapeutic
advances [2]. Five-year survival of patients with metastatic disease is only 21% while
that of patients with non-metastatic disease is 89-100%, and 1/3 of patients deemed
metastasis-free at diagnosis develop distant metastasis after surgical removal of the
primary tumor [3]. These sobering facts remain even as the overall breast cancer death
rate has decreased by 36% from 1989 to 2012 in the United States [2]. This decrease has
largely been due to increased emphasis on early detection and some improvements in the
effectiveness of available therapies [4]. However, there is still a great need for further
development of more effective therapies, especially for triple negative tumors, and to
reduce the harmful side effects associated with systemic chemotherapy and radiotherapy,
such as cardiomyopathy, peripheral neuropathy, neurocognitive dysfunction, decreased
fertility, and the induction of secondary cancers among others [5]. Immune therapies
present promising alternatives with a theoretically more targeted activity and more
durable clinical response with fewer long-term negative effects.
1

1.2 BREAST CANCER CLASSIFICATION AND CHARACTERIZATION
Human breast cancer is divided into two overarching categories based on whether
or not the disease has spread; namely, in situ carcinoma, which consists of cellular
abnormalities and resulting distortions of ductal and lobular tissue, and invasive
carcinoma, which has breached the basement membrane of the glands from which it
originated. The majority of clinically identified cancers are invasive, and prognosis is
largely determined by staging and subtype [2].
Staging is the extent to which the invasive carcinoma has spread at the time of
diagnosis, and there are two widely used systems for quantifying this: the Surveillance,
Epidemiology, and End Results (SEER) Summary Stage and TNM Staging. The TNM
classification is most often used in clinical settings and is determined by the following
three factors: how far the primary tumor has spread within the breast and adjacent tissues
(T), the extent to which tumor cells have colonized draining lymph nodes (N), and the
absence or presence of metastasis in distant organs (M) [6]. A stage of 0 to IV is then
assigned based on the TNM assessment with 0 being in situ and IV being advanced
metastatic disease.
There are two major subtype classifications: histological, of which there are 21,
and molecular, of which there are at least four [7, 8]. These molecular subtypes are most
often determined by the presence or absence of hormone (estrogen and progesterone)
receptors (HR+/HR-) and the overproduction of human epidermal growth factor (HER2).
Conveniently these biological markers can also be used as therapeutic targets, and often
to great effect, making certain molecular subtypes demonstrably more treatable than
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others. These four subtypes are generally as follows: luminal A (HR+/HER2-), luminal B
(HR+/HER2+), HER2-enriched (HR-/HER2+), and triple negative (HR-/HER2-) [9-12].
Luminal A is the most common (74% of tumors), least aggressive, and the most
quickly responsive to therapy, especially hormonal therapy, and is associated with the
best prognosis of the four subtypes [13]. Luminal B tumors make up about 10% of breast
cancers and are more aggressive than luminal A, often containing a high proportion of
actively dividing cells [14]. With the recent advent of HER2-targeted therapies in
addition to hormone therapies, the prognosis for luminal B tumors is improving. HER2enriched tumors make up only 4% of all diagnosed breast cancers, and tend to be very
aggressive with a poor prognosis in the absence of HER2-targeted therapies, which have
proven highly effective [13]. Triple negative cancers are the most difficult to treat. Triple
negative breast cancer is more common in younger women, African Americans, and
those with BRCA1 gene mutations, though recent studies have shown that the increased
prevalence among African Americans is not related to BRCA1 [15]. The vast majority
(~86%) of triple negative breast cancer is basal-like based on gene expression profile in
contrast to the other three molecular subtypes, none of which are more than 11% basallike [16]. Basal-like breast cancers are so named because they express a pattern of
markers consistent with the basal layer of the breast ductal epithelium [17]. With no ER,
PR, or HER2 to target, clinicians are limited to surgical resection, radiotherapy, and
cytotoxic chemotherapy. There are currently few targeted therapies for triple negative
tumors, and thus this breast cancer subtype has the least favorable short-term prognosis,
but is the focus of a great deal of study in order to understand its molecular background
and translate this to targeted therapy [13, 18-20].

3

1.3 BREAST CANCER TREATMENT
Treatment regimens for breast cancer are largely determined by the stage and
molecular subtype as well as patient characteristics, such as age and menopausal status
[2]. In general tumors discovered at earlier stages merit some type of surgical
intervention combined with adjuvant therapies to reduce the likelihood of recurrence.
Successful treatment options for late-stage, metastatic disease are more limited, and
systemic chemotherapies or targeted therapies are key due to the fact that removal of the
primary tumor has little beneficial impact on overall survival once the cancer has spread
[2].
Surgical intervention often serves a dual purpose, to both remove the dysplastic
tissue and aid in accurately staging the disease. The most common two surgical
procedures currently performed are mastectomy (complete removal of the breast) and
breast-conserving surgery (BCS), which involves removal of the tumor itself and a
margin of normal tissue. Both BCS and mastectomy are often accompanied by removal
of a few axillary lymph nodes, sentinel lymph node biopsy (SLNB), in order to determine
staging, whether or not to perform further surgery, and to guide chemotherapy decisionmaking [21]. Patients are increasingly opting for mastectomy over BCS even though
long-term outcomes are very similar for these two interventions, while BCS does yield a
higher rate of local recurrence [22-24]. Patient studies have found that this is because of
reluctance to undergo radiation therapy, which is more often recommended with BCS,
and patient fear of recurrence after less aggressive BCS surgery [25]. Modified radical
mastectomy, removal of the entire breast and axillary lymph nodes, is also performed in
some cases if patients elect to peruse this route, but the risk of lymphedema, severe
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swelling of the arm due to impaired lymph drainage, discourages some, though there are
successful physical therapies for this condition [26, 27]. Traditional radical mastectomies,
in which the muscles of the chest wall are also removed, are very rarely performed and
are not necessary to adequately remove most cancers. However, the rate of bilateral
mastectomy, or contralateral prophylactic mastectomy (CPM) is increasing. While this
does eliminate the risk of developing future breast cancer, it has not been shown to
increase long-term survival and is more closely associated with a number of harmful
outcomes including mortality [28-33].
Radiation therapy often accompanies surgery, especially BCS or when a small
number of tumor cells are found upon SNLB, and full axillary lymph node dissection is
not performed [34, 35]. It employs appropriately shaped beams of ionizing radiation or an
implanted radioactive source (brachytherapy) to damage the DNA of and kill tumor cells,
often using intersecting low-energy beams to limit damage to adjacent tissue [2]. In the
case of BCS, adjuvant radiation therapy has been demonstrated to reduce breast cancer
recurrence by about 50% and the relative risk of death due to recurrence by about 20%
[36]. The most common implementation is whole breast radiation for three to seven
weeks [37]. Brachytherapy has been shown to be more likely to have complications, such
as infection, and still requires a subsequent full mastectomy more often than whole breast
external radiation, though any radiotherapy is not without side effects.
The other common component of breast cancer treatment is systemic therapy,
referring to any treatment to which the entire body is subjected due to its distribution via
the circulation. This includes chemotherapy, targeted therapy, immunotherapy, and
hormone therapy. These treatments are usually administered either before primary
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surgical intervention (preoperative or neoadjuvant) or after (adjuvant). It is often
advisable to attempt to shrink larger tumors via neoadjuvant therapy in order to reduce
the complexity of resection. Additionally, systemic neoadjuvant therapy has been shown
to be as effective as adjuvant therapy at increasing survival, and decreasing metastatic
recurrence [38]. After all, the main purpose of adjuvant chemotherapy is to destroy
disseminated cancer cells and micrometastases, and neoadjuvant therapy likely has a
similar effect. Due to this ability to kill tumor tissue throughout the body, high stage,
metastatic disease is primarily treated with systemic therapy, as primary tumor surgical
resection has little impact on the total disease burden. The decisions about which
systemic therapies are appropriate are governed by tumor stage, molecular subtype, and
occasionally genetic panels such as Oncotype DX and PAM 50, which can help to predict
the risk of metastatic recurrence [2].
Traditional chemotherapies are more deadly to rapidly proliferating cells than
more quiescent ones. This makes them generally more effective against more aggressive
tumors such as those overexpressing HER2 and triple negative cancers [39].
Chemotherapy is the most commonly prescribed therapy for triple negative tumors
regardless of stage due to the complete lack of targeted therapies, with platinum
compounds, such as cisplatin, demonstrating clinical efficacy. However, recent massively
parallel sequencing has revealed that triple negative breast cancer itself is highly
heterogeneous and some forms may express molecules that could be potential therapeutic
targets such as androgen receptors [40]. No systemic chemotherapy is free of potentially
life-altering toxicities, driving the development of targeted/immune therapies to reduce
this collateral morbidity [41].
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The goal of hormone therapy is to either lower systemic levels of estrogen or
block its pro-tumor effects. Hormone therapy is of course most effective on luminal
tumors, especially luminal A tumors expressing both estrogen (ER+) and progesterone
(PR+) receptors. Until recently it was not known why such “double positive” tumors
were more susceptible to hormone therapy, because the progesterone receptor was not
directly targeted by most therapies, and ER+/PR+ patients received the same treatments
as ER+/PR- ones. Evidence now points to increased progesterone receptor activity
naturally counteracting the estrogen-mediated proliferation, and progesterone receptor
agonism may boost the effectiveness of estrogen receptor antagonism [42]. Compared to
chemotherapies, hormone therapy is usually implemented for much longer after the
primary surgical intervention takes place. Tamoxifen, a selective estrogen receptor
modulator (SERM) and one of the most common hormonal therapies, when given for at
least five years post-surgery, reduced the rate of recurrence by 40-50% over the 10-year
period following surgery and reduced mortality by about 30% 15 years after diagnosis
[43]. More recent studies have demonstrated that even longer use of tamoxifen yields
even greater benefit [44, 45]. In addition to SERMs, aromatase inhibitors (AIs) are
commonly used to treat HR+ breast cancer. The aromatase enzyme converts testosterone
to estradiol and androstenedione to estrone, thus inhibiting this enzyme, reduces total
available estrogens produced in the adrenal glands, but has no effect on ovarian estrogen.
For this reason AIs are more effective in post-menopausal women and often considered
an adjunct therapy to SERMs. These hormonal therapies, while effective for HR+ tumors,
are not without side effects related to starving the body or specific tissues of estrogen
stimulation such as menopausal symptoms and osteoporosis.
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A number of targeted therapies are now available for tumors overexpressing
molecules related to increased proliferative activity. Several of these target HER2;
trastuzumab and pertuzumab are monoclonal antibodies against different regions of the
HER2 protein. Trastuzumab has been demonstrated to reduce the risk of recurrence in
early stage, HER2-enriched tumors by about 50% relative to chemotherapy alone [46].
Ado-trastuzumab emtansine is a combination molecule consisting of the same antibody
found in trastuzumab and the chemotherapy drug emtansine (DM-1). The HER2 antibody
preferentially carries what would be a systemic chemotherapy to the tumor, thus
decreasing side effects and increasing the tumoricidal effect [47]. Other approved
targeted therapies block cyclin-dependent kinases (CDKs) involved in cell proliferation
and mTOR, a protein that promotes angiogenesis and proliferation, and there are many
more currently in development [48-51]. A noteworthy issue with these therapies is that all
of these targets are the body’s native molecules which are just aberrantly expressed in
breast cancers, thus even these therapies are not targeted to only the tumor cells.
1.4 CANCER IMMUNOTHERAPY
The targeted therapies discussed in the previous section are all antibodies, and are
thus referred to as passive immunotherapies [52]. Any directly tumor-targeting antibody
or adoptive cell therapy is considered a passive immunotherapy, while cancer vaccines
and directly immune modulatory antibodies (such as checkpoint blockade) are considered
active immunotherapy [52]. The only immune modulatory antibody currently approved
for the treatment of breast cancers with some genetic characteristics is pembrolizumab, a
humanized IgG4 isotype antibody against lymphocyte PD-1. In 2017 the FDA approved
the use of pembrolizumab for metastatic solid tumors with genetic anomalies such as
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microsatellite instability and mismatch repair deficiency [53]. Two of the most significant
reasons why the subset of tumors for which this drug can be used is so small are: (a) not
all tumors express elevated levels of PD-L1 and (b) blocking the interaction between PD1 on leukocytes and PD-L1 fosters the immune-mediated destruction of the PD-L1
expressing tumor, but also can induce severe autoimmunity resulting in conditions such
as Crohn’s disease, lupus erythematous, and rheumatoid arthritis [54]. Other PD-1 and
PD-L1 antibodies have shown promising results in breast cancer studies and several are
currently undergoing breast cancer-specific clinical trials, but response rates remain at
about 15-30% when used as a monotherapy. Modifications to PD-L1 antibodies, such
glycosylation via B3GNT3 glycosyltransferase, have increased this response rate
significantly, but so far only outside the clinical setting [55]. CTLA-4 blocking
antibodies, such as ipilimumab, have been approved for some cancers, but not breast
cancer, and present a higher risk for life-threatening autoimmunity than PD-1/PD-L1
interference [56]. Several other checkpoint inhibitors have been investigated, and some,
including TIM-3 blocking antibodies, have demonstrated potential to increase
proliferation and cytokine release from tumor antigen-specific T cells, but none have
been approved for clinical use [57, 58].
Another emerging immune therapy for solid tumors involves adoptive transfer of
tumor specific T cells. There are several such strategies including expansion of tumorinfiltrating lymphocytes (TILs) and retrovirus-encoded T cell receptors, but most
commonly this is achieved by genetically modifying the patient’s own T cells to express
a chimeric antigen receptor (CAR-T cells) [59]. The CAR itself often consists of the
variable region of a monoclonal antibody to a tumor-expressed antigen which has been
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grafted onto the internal signaling domains of the T cell receptor and, in newer iterations,
other costimulatory molecules such as CD28 [60]. This strategy has proven quite
effective against leukemia, but many solid tumors, including breast cancer, do not
respond significantly to such therapies [61]. Some recent studies, however, have
uncovered effective CAR-T targets, even on TNBC, and show promising results,
including regression of primary tumors and lung metastases of human cancers implanted
in immune deficient mice [62]. The promise of CAR-T cell therapy is not without its
drawbacks. The most significant of these stems from the fact that the engineered T cells
are highly effective at killing the tumor. In malignancies for which CAR-T cell therapy
has been approved, especially if there is a high disease burden, such targeted cells can
sometimes elicit the release of enormous amounts of pro-inflammatory cytokines, termed
cytokine release syndrome (CRS). Release of large quantities of cytokines such as IFN-γ,
IL-6, and GM-CSF can cause fever, shock, and liver failure. It is for this and other
reasons that CAR-T cell therapy is often seen as a “double-edged sword”, and coadministered inhibitors of some of these off-target effects may prove useful [63].
Cancer vaccines move a step beyond checkpoint blockade in complexity of
implementation, and hold promise as both adjuvant and long-term preventive therapies
for patients with higher likelihoods of recurrence. The goal of these therapeutic vaccines
is to sensitize the patient’s immune system to specific epitopes either unique to or
enriched on the tumor cells, thus allowing the relatively specific targeting and destruction
of the cancer by the patient’s own immune cells. Tumor cell destruction then releases
additional cytokines and antigens that further boost and focus the immune response,
which can be sustained long after treatment has ended [64]. This immunologic memory
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allows the body to seek out and destroy the cancer systemically and stave off recurrence
from disseminated micrometastases. The main challenges with this approach are to
identify ideal tumor associated antigens (TAAs) which both are unique and produce an
effective immune response. The identification of TAAs has been taking place since the
late 1970s. The majority of these early endeavors were focused on mutations in what
were then newly discovered cancer-causing genes and the aberrant proteins transcribed
from them. Vaccines based on the proteins derived from oncogenes, and fusion proteins
(such as BCR-ABL-1) were shown to be effective in mouse models and were tested
clinically with mixed results. Proteins from oncogenic viruses such as human papilloma
virus (HPV) and Epstein-Barr virus (EBV) have also been investigated. Patients with
relevant virus-mediated cancers did possess limited numbers of T cells specific for viral
proteins, but while results in mouse models were promising, none of these vaccines
demonstrated clinical efficacy [65-67]. Since that time, more traditional preventive
vaccines have decreased the incidence of several important oncogenic viruses and the
malignancies often arising from chronic infection. Hepatitis B virus (HBV) vaccination
efforts promise to prevent 1.5 million hepatocellular carcinoma (HCC) related deaths
over the next 12 years, and human papilloma virus (HPV) vaccines have not only
demonstrated drastic decreases in the incidence of both cervical and oral cancers, but
have also resulted in the regression of extant neoplasia in some clinical trials (100%
regression among some patient cohorts) [68-73]. Where these and other vaccines have
previously only been tested as treatments, improvements in technology and a change in
perspective have led to overwhelming success as preventative measures. There have also
been efforts to use TAAs in the development of preventative vaccines for non-viral
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mediated cancers in high risk patient populations. More recent efforts along these lines
have been met with some success, especially with the TAAs MUC1 (here in ovarian
cancer, though also implicated in some breast cancers) and HER2 [74]. This is likely
because both of these antigens are required for the growth and development of their
respective malignancies, and losing them to escape immune destruction would likely
bring little selective advantage for the tumor.
One problem with the early therapeutic vaccine efforts is the fact that the vast
majority of tumor antigens to which there is an adaptive immune response are nonmutated proteins which are overexpressed in tumors. The early focus was on peptide and
peptide plus adjuvant designs, similar to preventative vaccines, but since 1990
overexpressed TAAs have become the focus of vaccine design. Some of the first attempts
at breast cancer vaccination were peptide vaccines using the familiar marker HER2, and
at least one such HER2-peptide vaccine therapy, nelipepimut-S, is currently undergoing
phase III clinical trials. Nelipepimut-S is a nine amino-acid peptide (E75) from the
extracellular domain of HER2 [75]. Many patients with HER2-expressing breast cancer
have been found to already have some level of immunity to E75 antigen, and in this
subset of cancers, it has demonstrated clinical benefit [76].
As the importance of dendritic cells (DCs) as professional antigen presenting cells
became clear over this time period, and the techniques required to generate large
quantities of autologous DCs were developed, these cells came to be viewed as the best
vehicles for antigen delivery and initiation of a tumor-specific adaptive immune response.
Hundreds of DC-based vaccine trials were carried out for many different cancers [77,
78]. Viruses, virus-like particles, and bacterial vectors were also engineered to carry
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tumor antigens as vaccines [75, 79, 80]. Emerging knowledge of the stimulatory effects
of toll-like receptor (TLR) agonism on antigen presenting cells led to the inclusion of
TLR ligands as adjuvants in vaccines to more robustly activate the immune system. In
spite of all of these advances and refinements, most of these vaccines had little impact on
disease-free survival, overall survival, or recurrence [81]. In order to shed light on the
reasons for these shortcomings and guide future vaccine development, several metaanalyses have been performed on hundreds of these trials. A key conclusion from these
meta-analyses is that the vast majority of vaccines phase II trials did not demonstrate
statistically significant benefit and never moved on to phase III (only 4% did). This likely
may have been due to the limited duration of outcome monitoring, and none of the
studies analyzed contained long term (>10 years) follow-up statistics. However, 12-year
survival rates have recently been reported for an ex vivo matured autologous DC vaccine
against non-resectable metastatic melanoma. 19% of these patients were alive after this
lengthy period of time, an impressive result for an aggressive disease with a normally
very poor prognosis. This result is comparable to treating similarly severe melanoma with
FDA-approved CTLA4 checkpoint blockade therapy [82].
Though no breast cancer vaccines are currently available, many either have been
or are currently under development. The first, and only true, FDA-approved cancer
vaccine, sipuleucel-T, was approved for the treatment of hormone-resistant metastatic
prostate cancer in 2010, but no such vaccines have been approved thus far for any other
malignancies [83]. Sipuleucel-T is a DC-based vaccine. Its implementation involves the
extraction of the patient’s own circulating monocytes, which are then incubated with a
fusion protein called PA2024 made up of granulocyte monocyte stimulating factor (GM-
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CSF) and prostatic acid phosphatase (PAP), an antigen present in almost all prostate
cancer cells. This stimulates the differentiation of the immature monocytic cells into DCs
as well as their maturation into effective presenters of the provided tumor antigen, PAP.
These cells are then re-infused into the patient three times over a 6-week period [84]. To
date, two phase III clinical trials have demonstrated a modest, but statistically significant
increase in patient survival after sipuleucel-T treatment.
Another possible reason for the failure of these vaccines could have been the fact
that the participants in most of these trials were patients with advanced disease and,
likely, significant immune suppression. Even mature DCs bearing potently immunogenic
antigen were insufficient to overcome this environment and carry out the desired
tumoricidal activity. To combat this, there are three obvious avenues by which better
vaccine success rates may be achieved, all of which may in the end be combined for
maximal effect. First, more complex vaccines containing many potentially effective
tumor antigens and adjuvants may provide more robust immune stimulation than the
single antigens tested in the majority of these trials. Second, enrolling patients with early
stage disease might allow the introduction of vaccine material into a less immunesuppressive micro-environment, where it stands a better chance of beneficially increasing
the patient’s own antitumor immune response. Third, ex vivo genetic manipulations of
autologous DCs may increase their capacity for maturation and decrease their
vulnerability to intratumoral immunosuppression, again allowing the vaccine to better
carry out its function as intended [85].
Several more recent clinical trials of DC-based vaccines in patients with premalignant breast lesions, ductal carcinoma in situ (DCIS), have demonstrated favorable
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results. These have taken advantage of the effectively immunogenic TAA, HER2. One
such trial used the following strategy. Four weekly autologous DC vaccinations were
administered to 13 patients prior to surgery. These DCs, loaded with HLA class I-binding
and HLA class II-binding HER2-derived peptides, were matured and activated in vitro. In
order to maximize the immune response and ideally place the DCs for successful tumorprimed T cell interaction, the vaccine was injection into regional lymph nodes likely to be
draining the tumor bed. All patients developed HER2 peptide-specific CD4+ and CD8+
cells as well as a robust tumor-lytic antibody response. ~64% of patients were found to
have a decreased DCIS burden at surgery and remaining DCIS contained a significant T
and B cell infiltrate. Accompanying this decrease in tumor size, HER2 expression was
also decreased, which also likely had a direct impact on tumor cell survival [86]. A
second trial, in which 27 patients with DCIS participated, replicated these favorable
results. After following the same vaccination schedule, five of the 27 patients were found
to have no evidence of DCIS at surgery. Half of the remaining 22 patients had lost their
HER2 expression [87]. Thus far, there has not been follow-up or disease outcome data
collected for these studies, but as the prognosis for DCIS is usually quite good, a high
long-term survival rate and low incidence of recurrence would be expected even without
this increased tumoricidal immune response.
During the early period of cancer therapeutic vaccine development, the induction
of systemic immune suppression by the tumor was largely unknown, but since that time,
many mechanisms of immune suppression have been discovered and provide potential
immune therapeutic targets. It is very likely that groups of these strategies will be shown
to function well together, and just as tumor cells take advantage of many mechanisms to
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compromise host immunity, treatments will need to counteract these efforts on multiple
fronts simultaneously. Some of the primary immune suppressive cell populations that
have been targeted are monocyte-derived suppressor cells (MDSCs) and tumor associated
macrophages (TAMs). Multiple aspects of these cells have become the focus of proposed
therapeutic perturbations whether through blocking growth factor receptors such as CSF1 [88], altering metabolic pathways such as fatty acid oxidation or glycolysis [89], or
blocking the activity of certain key enzymes such as indoleamine 2,3-dioxygenase 1
(IDO1) [2, 90-92]. Combinations of these innate immune therapies, checkpoint
inhibition, T cell transfer, and therapeutic vaccines may have the most significant and
universal antitumor effects [93]. The relative successes of checkpoint inhibition and
CAR-T cells, coupled with new data supporting the inclusion of therapeutic vaccines as
part of combination immunotherapy, has led to a significant recent increase in enthusiasm
for therapeutic vaccine development as a part of a multi-pronged approach.
As the breast cancer molecular subtype with the most limited number of treatment
options, TNBC is often the focus of new combination immunotherapeutic approaches.
The only completed clinical trial to date testing the efficacy of immune checkpoint
inhibitors on TNBC, specifically, demonstrated a benefit to only a limited number of
patients [94]. Oncolytic virotherapy has been found to enhance general antitumor
immunity, reduce forced recurrence, and render TNBC more vulnerable to checkpoint
blockade in murine studies [95, 96]. Studies into TNBC genomic data has yielded a
surprising, and fortuitous finding. Almost all of the immune activation pathways were
enriched to a significantly higher degree in TNBC versus non-TNBC [97]. This means
that it may be the case that while TNBC expresses no traditionally targeted antigens, it is
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the most immunogenic molecular subtype and may be the most vulnerable to immune
therapy. The majority of immune checkpoint genes, including CTLA4 and PD-1, are
overexpressed in TNBC compared to non-TNBC and normal tissue. There is also a much
higher density of tumor-infiltrating lymphocytes in TNBC than non-TNBC, though it is
important to remember that many of these cells are immune suppressive and would be
negative prognostic indicators. However, it was found that CD57 expression was more
abundant in TNBC than in non-TNBC; CD57 is a marker of activated T and NK cells.
Other proinflammatory genes such as IFNγ and IRF1 are also enriched in triple negative
tumors [97]. Overall the genomic profiling of these tumor samples paints a picture of
TNBC as both a highly immunogenic and highly metastatic tumor which may prove a
fruitful target for checkpoint inhibition, therapeutic vaccination, and various combination
immunotherapies.
The future success of cancer immunotherapy will depend on the rapid
identification and/or use of novel immunogenic antigens. Delivery of these antigens by
the optimal vehicle, such as DCs, viruses, or some other yet to be discovered mechanisms
will also be key to future therapeutic success. Coupling these therapies with adjuvants
and immune modulatory treatments such as checkpoint blockade, IDO1 inhibition, or
other innate immune therapies will allow for the more comprehensive targeting of the
breast cancer immune regulatory network and improved therapeutic success. In the
experiments described here, the development of two immune therapeutic modalities and
strategies are discussed. Each is intended to both bring basic murine models of
experimentation closer to the patterns of clinical application and to further the
development of two immune therapies toward use in human patients. The first of these
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therapies is emodin, a natural compound derived from several herbs used in traditional
Chinese medicine (TCM) [98]. It has been shown to have numerous immune modulatory
properties [99-102], but our lab was the first to demonstrate its ability to attenuate breast
tumor progression through its effect on macrophage-cancer cell interaction [103]. Here
emodin is tested in a murine model of tumor resection as an adjuvant therapy to prevent
metastatic recurrence of triple negative breast cancer. Its proven low toxicity and ability
to disrupt the reciprocal signaling between tumor cells and macrophages make it a
promising innate immunotherapy [104]. The second therapeutic strategy involves genetic
modification of DCs to increase their immune stimulatory capabilities and the
implementation of these modified DCs as therapeutic breast cancer vaccine. Our lab was
again the first to reveal the role of microRNA-155 (miR155) as a key regulator of DC
function and mobility [105]. We have previously demonstrated that total-body knockout
of miR155 increased both tumor growth and metastasis in an orthotopic model of murine
breast cancer; here total immune system overexpression of miR155 and a miR155overexpressed DC vaccination therapy are shown to suppress murine breast tumor
progression. Some of the relevant parameters of DC maturation, migration to draining
lymph nodes, and activation of T cells are also investigated using these miR155overexpressed DCs.
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CHAPTER 2
GENERATION OF A MOUSE MODEL FOR TRIPLE-NEGATIVE BREAST
CANCER POST-SURGERY METASTATIC RECURRENCE
2.1 BACKGROUND
Historically, the drug development process for cancer therapeutics has relied
heavily on preclinical murine models to determine the effectiveness of treatments in vivo.
Especially in the case of using immune deficient mice bearing human cancer cell lines or
explants, these models have had difficulty in predicting treatment efficacy for patients
[106, 107]. The tumor microenvironment in a largely immune competent human is often
found to respond very differently to treatments leading to many failed clinical trials [108,
109]. In order for mouse models to be more predictive of clinical success, whenever
possible it is advantageous to use immune competent mice. The interplays between tumor
cells, immune cells, and other stromal cell populations determine the efficacy of therapies
in patients where these interactions also shape disease progression. This is particularly
true when testing targeted therapies and immunotherapies [108, 109]. It is also very
common for studies to not focus on the most appropriate measures of therapeutic success
or endpoints. Many murine studies of cancer progression focus on inhibiting tumor
growth and monitor it as the key phenotypic finding, with a reduction in final tumor
weight indicating positive therapeutic benefit. While reduction in tumor size is a
welcome clinical outcome, it is usually only a minor component of overall therapeutic
goals related to easing surgical excision or a step toward eradication of a highly
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invasive/disseminated malignancy (which has a relatively low success rate).
Overemphasizing primary tumor growth retardation can sometimes lead to the use of
therapies that simultaneously encourage metastatic spread and local recurrence. This is
the case with some systemic cytotoxic therapies, and has been largely attributed to the
induction of a pro-tumor immune response to the dying tumor cells [110-113]. Clinical
outcomes are usually measured in terms of progression-free survival and overall survival,
criteria that often largely depend on the degree of tumor metastatic progression after
treatment [114]. Preclinical, immune-competent murine models mirroring the treatment
strategies and schedules actually used to treat human breast cancer should serve as a
better predictor of patient outcomes when/if therapies progress to clinical testing [115].
In an attempt to do just this, we have established a murine model of highly
metastatic TNBC, which as closely as possible, seeks to imitate the progression from of
diagnosis to surgical excision and subsequent adjuvant therapy to prevent metastatic
recurrence experienced by breast cancer patients [116]. Non-invasive molecular imaging
was used to estimate the extent of metastatic dissemination leading up to and after
surgical resection. As the eventual purpose of the model is to test the effect of emodin
treatment on metastatic recurrence, the optimal traceable cell line, injection site, and
time-point for tumor resection have to be determined where metastases would eventually
arise in untreated mice but are not detectable at the time of surgery. This recurrence could
be the result of existing micrometastases or circulating tumor cells present at the time of
tumor removal, but exhaustive studies to parse this out have not been performed. At this
time for our phenotypic analysis, the broader measures of clinical outcome are most
relevant.
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2.2 PRELIMINARY TEST OF METASTATIC RECURRENCE MODEL
2.2.1 DETAILED MEHTODS
Tumor models
7 week-old, female BALB/c mice were purchased from Jackson Labs (Bar
Harbor, ME), and were housed at the University of South Carolina Animal Research
Facility for one week prior to experiments. All procedures were approved by the
University of South Carolina Institutional Animal Care and Use Committee. 4T1-luc2RFP cells were generated by transducing 4T1-luc2 cells (PerkinElmer, Waltham, MA)
with pWPI-RFP lentivirus. The resulting 4T1-luc2-RFP cells were sorted using a FACS
Aria II (BD Biosciences, San Jose California) and stored in liquid nitrogen. 4T1-luc2RFP cells were recovered from liquid nitrogen storage and passaged not more than three
times to expand before inoculating BALB/c mice. 4T1-luc2-RFP cells were washed twice
in PBS after harvesting with 0.05% Trypsin/EDTA and resuspended in PBS at a density
of 10x106 cells/mL. On Day 0, 30 8-week-old female Balb/c mice were bilaterally
injected with 2x105 4T1-luc2-RFP tumor cells in the 4th pair of mammary fat pads by
creating a 1 mm-long incision about 1 mm inferior to the nipple and using a short,
beveled needle for cell implantation. This blunt needle method was used to help ensure
delivery of the tumor cells into the fat pad tissue at a shallow depth without entering the
peritoneum. On Day 6, mice were separated into 3 groups based on equal average tumor
volume. On Day 8, hair was removed from the surgical field using a depilatory cream in
preparation for surgery. Tumors were allowed to grow for 10 days to a volume of ~200
mm3 before removal. Tumor volume was calculated using the following formula: (short
axis)2 x (long axis)/2 ≈ volume. The tumors were removed on Day 10. On Day 11, the
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three groups of mice received i.p. injections of PBS with 2% DMSO by volume
containing either 0 mg/kg, 20 mg/kg or 40 mg/kg emodin. The volume of these injections
was ~800 µL per mouse. These i.p. injections were administered daily for the next two
weeks. After two weeks of daily injections, injections were given every other day for two
more weeks. When mice died during the course of this study or exhibited significant
moribundity and were sacrificed, their lungs and other metastatic sites identified on IVIS
Spectrum (PerkinElmer) imaging were taken for counting of metastatic
nodules/determination of metastatic burden. On Day 42 the lungs of surviving mice were
removed for metastatic and immune cell population analyses.
Tumor removal procedure
Each mouse was anesthetized using an isoflurane vaporizer and maintained under
anesthesia for the duration of the surgery with the vaporizer set to deliver 2% isoflurane.
The surgical field was cleaned liberally with 70% ethanol and betadine swabs. A 1-2 cm
incision was made medial to the tumor, and the tumor, with as much surrounding fat pad
as possible, was resected. An electrocautery unit was on hand to stop excess bleeding if
necessary. Incisions were closed with stainless steel clips and suture. Mice were allowed
to recover in a cage heated to 30˚C.
IVIS Imaging
BALB/c mice bearing 4T1-luc2-RFP tumors were imaged using an IVIS
Spectrum (PerkinElmer). Prior to data collection, a kinetic curve was collected. To do
this, D-luciferin (Sigma-Aldrich Corp., St. Louis, MO) was dissolved in PBS at a
concentration of 15 mg/mL. Mice received 10 µL of this solution per gram body weight
intraperitoneally (i.p.), were anesthetized using an isoflurane vaporizer, and imaged at
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600 nm wavelength beginning 10 min after having received the D-luciferin injection.
Images were obtained once per minute for the next 30 min while the mice were
maintained under anesthesia at 1.5% isoflurane. Metastatic recurrence was monitored
using the IVIS Spectrum to image the luciferase activity in the 4T1-luc2-RFP cells using
the same imaging procedure described for kinetic curve determination, but only one
image was collected at 10 min. IVIS imaging began on Day 13 and continued weekly
until the termination of the experiment.
Flow Cytometry
Lung tissue was collected from the surviving mice on Day 42, cut into small
fragments and digested using the following mixture of enzymes in serum-free RPMI at
37˚C for 45 min: 10 mg collagenase IV (Worthington Biochemical Corp., Lakewood,
NJ), 10 µg hyaluronidase (Sigma-Aldrich Corp.), and 100 µg DNAse I (Sigma-Aldrich
Corp.). Red blood cells were then lysed in 3 mL RBC lysing Buffer (Sigma-Aldrich
Corp.) for 5 min at RT. 25 mL PBS was added and each sample pelleted by
centrifugation at 325 x g for 5 min. Cell pellets were resuspended in 10 mL PBS, passed
through a 70-µm cell strainer, and pelleted by centrifugation. Cells were counted and
1x106 cells from each sample was resuspended in 100 µL staining buffer (PBS 2% FBS).
Cells were blocked with Fc blocking antibody (Biolegend, San Diego, CA) for 10 min at
4˚C, then cells were stained with anti-CD3 FITC, anti-CD8 APC, anti-F4/80 FITC, and
anti-CD206 APC (Biolegend) for 30 min at 4˚C. Cells were then washed twice with PBS
and resuspended in 500 µL PBS for flow cytometry using a BD FACS Aria II and FACS
Diva software (BD Biosciences). 20,000 events were collected for each sample.
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Statistical Analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Two group
comparison of means was accomplished using a 2-tailed Student’s t test. All such
comparisons were performed using GraphPad Prism 5 software (Graphpad Software Inc.,
San Diego, CA). Differences between proportions were determined using a two tailed N1 Chi-Square test. Three group comparison of means was accomplished using a two
tailed ANOVA followed by Tukey multiple comparisons test p≤0.05 was considered
statistically significant for all tests.
2.2.2 RESULTS
The goals of this preliminary study were to (1) determine whether 10 days postorthotopic 4T1-luc2-RFP cell inoculation is a good time-point for tumor removal that
ensures appropriate metastatic recurrence rate; (2) test the general metastatic potential of
the 4T1-luc2-RFP cells and their tropism for lung tissue; (3) assess the survivability of
our surgical technique; (4) determine the timescale for metastatic recurrence; and (5)
determine whether emodin has an effect on metastatic recurrence. How well this model
met or shed light on each of these objectives will be discussed as well as the future
studies needed to fine-tune the method.
10 days of tumor growth was insufficient to achieve an appropriately high metastatic rate
with 4T1-luc2-RFP cells
There were no statistically significant differences between average tumor volume
or radiance between the groups prior to tumor resection as intended (Figure 2.1B&C).
Three days after tumor resection, and after only three treatments, two mice in the 0 mg/kg
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emodin group had obvious lung metastasis, and one of the mice in the 40 mg/kg emodin
group exhibited signs of local recurrence or residual tumor (Figure 2.1D). We intended
the surgery to completely eliminate the primary tumor, so this early local recurrence,
likely due to incomplete removal, was not ideal, but others have experienced significant
local recurrence when using a similar model [115]. The metastatic efficiency, or total
percentage of mice in each group that developed metastasis, was 40% for the controltreated group and 20% for both the 20 mg/kg and 40 mg/kg emodin-treated groups,
meaning in total only 26.6% of the mice developed metastases in any part of their bodies
(Figure 2.1E&F). Due to this very low metastatic efficiency across all groups, no
statistically significant differences could be determined.
Metastases did not occur preferentially in the lungs
From our IVIS imaging, in addition to very few of the mice ever developing
metastases, the majority of these metastases did not occur in the lung tissue. The majority
of highly bioluminescent regions that were obviously not local recurrence seemed to be
located in the jaw and shoulder areas of the mice (Figure 2.2A&2.1E). It was not
possible to determine whether these growths originated in lymph node or bone upon
necropsy or autopsy. Also what appeared on IVIS to be local recurrence on IVIS were
found at sacrifice to largely be metastases to the inguinal and hind limb region (Figure
2.2A&2.1E). Metastases occurred unpredictably with 4T1-luc2-RFP cells; other cell lines
with more reliable lung tropism may be better for our purpose. Allowing tumors to grow
longer in the mice before resection will also be considered.
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Mice were able to recover from surgery and metastases appeared quickly
None of the mice died as a direct result of the surgery in spite of the fact that two
of the mice did remove their wound clips during the recovery period immediately
following surgery and required re-suturing of their incisions. Also, all of the mice in
which metastases did arise developed these by two weeks post-surgery (Figure 2.3A).
This two week timeframe (~3 weeks since tumor implantation) is consistent with other
studies tracking the progression of 4T1 tumors [117].
Emodin treatment showed a decreasing trend in metastatic burden and an increasing
trend in overall survival
Our previous studies have shown that emodin not only reduces metastases when
administered shortly after tumor cell implantation but also when tumors are already
established [103, 118]. Here, though our metastatic efficiency is low and not specific to a
single location after the orthotopic tumors were removed, we show that emodin treatment
does appear to exhibit some trends toward decreasing metastatic recurrence after surgical
resection of the primary tumor and increasing overall survival. The observation of this
trend in this particular study is obscured by the fact that the only mouse that developed
what appeared to be local recurrence was in the 40 mg/kg (high dose) emodin group
(Figure 2.1E). This is most likely due to lack of experience performing the surgery and
not due to the treatment itself. In this high dose emodin group, this mouse was the only
one that developed lung metastases and may never have developed these had the primary
tumor been completely removed. When only chest radiance is considered as a measure of
metastatic burden, the high dose emodin group had the lowest overall metastatic burden
by a large margin, and the low dose emodin group fell between the control and high dose
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emodin groups in chest radiance until mice began to die due to the progression of their
disease (Figure 2.4A). Metastasis-free survival also exhibited a trend toward emodin
reducing metastatic recurrence, though it did not reach statistical significance (Figure
2.4B). Overall survival paralleled metastasis-free survival, but the low mortality rates and
small sample sizes yielded insufficient statistical power for differences to manifest
(Figure 2.4C). The surviving mice at the conclusion of the study were not bearing any
lung metastases (Figure 2.4D); nonetheless flow cytometric analysis was performed of
lung macrophages and CD8+ T cells. There was unsurprisingly no difference in the total
T cell burden in the lungs and only a slight, statistically insignificant increase in CD8
positivity among the mice receiving emodin treatment (Figure 2.4E). The F4/80 staining
yielded no positive cells, which further study revealed was due to excessively harsh
enzymatic digestion destroying the F4/80 expressed on the surface of the lung
macrophages.
2.2.3 DISCUSSION
The data from this experiment show that many of our objectives for this model
were not met, but do point toward ways of improving these deficiencies. First and most
importantly, 10 days of tumor growth prior to resection was not adequate to induce
enough metastases to be able to study the potential impact of therapies on metastatic
recurrence with reasonable sample size. Future studies will monitor lung fields with IVIS
imaging more frequently in order to attempt to gage when metastases begin to be visible.
Then a study similar to this one will be repeated with tumors being removed a few days
prior to this determined time of macro-metastasis establishment.
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This particular strain of 4T1-luc2-RFP cell also does not appear to have a highly
specific lung tropism in this fat pad injection followed by surgical resection model. The
original purpose of using this cell line was to (1) have a highly aggressive model of
TNBC, (2) be able to take advantage of the non-invasive molecular imaging afforded by
the luciferin to monitor metastatic recurrence, and (3) to be able to analyze the level of
red fluorescent protein (RFP) expression in a single cell suspension of lung tissue to
easily determine metastatic burden. For the purposes of this study, the least important of
these objectives is the presence of RFP to measure metastatic burden. This can be
determined by counting and quantifying metastatic area on serial sections taken at
measured intervals and stained with hematoxylin and eosin (H&E). It may be possible to
perform a metastatic kinetics study using 4T1-luc2 cells without the RFP in order to see
if these cells metastasize more predictably while still be monitored in vivo using the IVIS
Spectrum.
The surgical method seems adequate for yielding high survivability and relatively
low local recurrence. In future experiments a little more normal tissue around the tumor
will be taken in order to ensure clean margins, and it remains to be seen how feasible this
will be if tumors are allowed to grow larger to ensure a higher percentage of metastasisbearing mice. It may be more difficult to effectively close the larger incisions.
With macrometastases appearing within one to two weeks after surgical resection,
this timetable is quicker than expected, but adequate to administer several doses of
treatment before the development of overt metastases. It remains to be seen if allowing
the tumors to grow longer will affect the rate of metastatic spread. It is possible that the
trauma of surgical resection itself may aid in metastasis, so once again improvement of
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surgical technique may improve the overall outcome of studies using this tumor resection
model.
Due to the deficits in the model, it is not possible to definitively determine
whether or not emodin treatment affected metastatic recurrence. Once further studies are
performed to improve this model, it may be possible to observe more definitive results in
metastatic burden, progression-free survival, overall survival, and immune cell infiltrate
at the metastatic site due to adjuvant therapy with emodin.
2.3 4T1-LUC2-RFP METASTASIS TIME-POINT AND TROPISM
2.3.1 DETAILED METHODS
Tumor Model
BALB/c mice were housed at the University of South Carolina Animal Research
facility until 8 weeks of age for use in this experiment. All procedures were approved by
the University of South Carolina Institutional Animal Care and Use Committee. Tumor
cell implantation was performed as described previously. Briefly, 4T1-luc2-RFP cells
(PerkinElmer) were resuspended in PBS at a density of 10x106 cells/mL. On Day 0, 15
female Balb/c mice were bilaterally injected with 2x105 4T1-luc2-RFP tumor cells in the
4th pair of mammary fat pads. Tumor volume was calculated as stated before and was
measured every 3 days beginning at Day 11. Mice were divided into three groups of five
mice each with equal average tumor volume on the day that tumors were to be removed
from the first group of mice. This first resection took place, as described previously,
when the average volume reached 500 mm3. Tumors were removed from the second
group at 1000 mm3 average volume and the third group at 1500 mm3 average volume.
These volumes were reached on Days 18, 22, and 26, respectively, since tumor cell
implantation. Mice were imaged using the IVIS Spectrum (PerkinElmer) prior to tumor
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removal and weekly thereafter until the conclusion of the study. When mice died during
the course of this study or exhibited significant moribundity and were sacrificed, their
lungs and other metastatic sites identified on IVIS Spectrum imaging were taken for
gross determination of metastatic burden. On Day 52 the lungs of surviving mice were
removed for gross determination of metastatic burden.
IVIS Imaging
BALB/c mice bearing 4T1-luc2-RFP tumors were imaged using the IVIS
Spectrum (PerkinElmer) prior to tumor removal, and each cohort of mice was imaged
after tumors were resected in order to gage the completeness of resection and presence of
metastasis at the time of tumor removal. Mice were then imaged weekly thereafter. Mice
were allowed to recover for 10 min in order for the D-luciferin to fully perfuse the mouse
and were then re-anesthetized and imaged at 600nm wavelength. Photons/second was
used to determine the luminous flux from the tumor cells and adjust for differences in
exposure time.
Statistical Analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Three group
comparison of means was accomplished using a two tailed ANOVA followed by Tukey
multiple comparisons test, while two group comparison was accomplished using a two
tailed Student’s t test. All such comparisons were performed using GraphPad Prism 5
software (Graphpad Software Inc.). Differences between proportions were determined
using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for
all tests.
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2.3.2 RESULTS
This study was performed to determine the amount of time required between 4T1luc2-RFP cell inoculation and tumor resection in order to achieve ≥80% metastatic
recurrence rate under control/untreated conditions. The secondary purpose of this study
was to again observe the metastatic tropism of the 4T1-luc2-RFP cells and determine
whether lung metastasis alone could be used as a measure of metastatic recurrence. If the
metastatic pattern is too erratic, then quantification of total body metastases and
observation of the effect any treatment may have on this would be much more difficult.
Our previous study had shown that 10 days of tumor growth, producing a 200 mm3 tumor
prior to resection, was too little time for the tumor to metastasize in a majority of the
mice, and many of the metastases that did occur formed outside of the lungs.
The metastatic tropism of 4T1-luc2-RFP cells following primary tumor resection is not
lung-specific
The average tumor volume of all tumor-bearing groups was the same at the time
of each tumor surgery, when multiple groups were still bearing tumors, as intended
(Figure 2.5B). The average tumor radiances were also the same at each of these timepoints (Figure 2.5C). The increasing average tumor weights at each of the sequential
resections mirrors the increasing volume measurements, and proves to be a much less
variable indicator of tumor size than the radiance data collected from the IVIS Spectrum
(Figure 2.5D).
Upon tumor resection, mice in each group were imaged using an IVIS Spectrum
to determine whether or not the entire tumor had been resected and the locations of any
pre-surgical metastases. After the first group of tumors had been removed on Day 18
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(Group 1), one of the mice presented with residual local tumor tissue upon Day 19 IVIS
imaging (Figure 2.5E). After the second resection on Day 22 (Group 2), one of the mice
in Group 1 seemed to exhibit an established lung metastasis, but none of the Group 2
mice appeared to have any residual tumor or metastases on Day 23 IVIS imaging (Figure
2.5E). Upon resection of the third group of tumors (Group 3) on Day 26, three out of the
five mice were found to already possess distant metastases, two of which were in the lung
fields on Day 27 IVIS imaging (Figure 2.5E). The third was located in the shoulder/jaw
region as observed previously when testing this model. One of these lung metastasisbearing mice also presented with substantial residual tumor tissue at one of its excision
sites. One of the mice in Group 2 presented with a non-lung distant metastasis, and three
mice in Group 1 appeared to exhibit some rapidly growing local recurrence. One of these
mice also still seemed to show the previously noted lung metastasis (Figure 2.5E).
Before the next IVIS Spectrum imaging on Day 38 post tumor implantation, two mice in
Group 3 died, necropsy showed that these deaths were likely due to metastatic spread of
the tumor. One of these mice had significant residual tumor and lung metastases obvious
on IVIS Spectrum imaging, while the other was found to have some relatively small lung
metastases on necropsy as well as a substantial tumor in the jaw/neck region (Figure
2.5E). Day 45 IVIS Spectrum imaging revealed that of the five mice in Group 1, one
appeared to still have a relatively stagnant local recurrence, while another of the mice
exhibited bilateral local recurrence and lung and other metastases. One of the mice in
Group 2 showed a potential local recurrence and a large shoulder metastasis. Of the three
remaining mice in Group 3, one still exhibited a large lung field metastasis (Figure
2.5E).
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Gross lung metastases only developed after 26 days of tumor growth before resection
The final IVIS Spectrum imaging was done on Day 52 since tumor cell
implantation. On this date, another mouse in Group 3 died, and though it was not
apparent that lung metastases were present in previous images, many large metastases
were present on necropsy (Figure 2.6A). Another mouse in Group 3 that had exhibited a
lung metastasis for the past several weeks was also moribund and would have required
sacrifice even if this had not been the final day of the experiment. Two of the mice in
Group 1 were sacrificed due to impairment brought on by their metastases prior to Day
52 imaging, both exhibited what appeared to be metastases upon necropsy, yet none were
present on the lungs. All of the metastases visualized on IVIS Spectrum imaging of
Group 1 mice were located, and even those appearing to be in the region of the lung
fields were either outside of or originating from the ribcage. Mouse #1 in this group
appeared to have a local recurrence from IVIS Spectrum imaging, but necropsy showed
that this was found to be associated with the muscle/bone of the hind limb, and did not
appear to originate from the primary tumor site. All of the mice in Group 2 survived until
termination of the experiment, though two appeared to bear tumor cells in various
locations on IVIS spectrum imaging. Interestingly, when all of mice were sacrificed, it
was found that none of the surviving mice from Group 2 had any lung metastases, and
only one metastasis was present on the lungs of one of the Group 1 mice, yet all three of
the Group 3 mice examined did exhibit lung metastases (Figures 2.6A&B). Thus, there
were only 3 mice in Group 1, 5 mice in Group 2, and 3 mice in Group 3 that survived
until the end of the study.
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2.3.3 DISCUSSION
The results of this study were at times difficult to interpret during its course, and
the most important finding was only apparent once all mice had been sacrificed. Only the
26-day tumor resection time-point yielded ≥80% lung metastases. Only a single
metastatic nodule was observed on the lungs of mice with tumors removed at either of the
earlier time-points. This was the case even with the single instance of local recurrence in
Group 1, which still exhibited no lung metastases. These findings indicate both that the
tumors must be allowed to grow for a great deal more time that originally suspected in
order to reliably (≥80%) yield lung metastases and that the 4T1-luc2-RFP cell line
continues to produce a substantial proportion of extra-pulmonary distant metastases.
Allowing the tumors to grow to the substantial volume of 1500 mm3 made clean resection
much more difficult and caused there to be less skin available to properly close the
incisions from which the tumors had been removed.
Both of these findings pose their own problems and the following potential
solutions are proposed. First, to attempt to solve the difficulties in resecting such large
tumors, only a single tumor injection into the right, 4th (9th) mammary fat pad will be
performed in subsequent studies. This should allow enough tissue to remain to effectively
close the excision site even if more tissue is taken to leave clean margins on a larger
tumor. Second, to attempt to both shorten the time to micrometastasis establishment and
identify a tumor cell line with more specific lung metastatic tropism, 4T1-luc2 cells will
be used. Studies comparing these two cell lines and others expressing one or multiple
tagging proteins have shown that adding more of these “useless” proteins can adversely
affect tumor progression and ever serve as immunogenic antigens [119]. We have also

34

shown that not all of the 4T1-luc2-RFP cells express high enough levels of RFP to
distinguish them from the native tissue, and thus it is unlikely that they can fulfill their
originally intended purpose as an easy target to determine lung metastatic burden.
Additionally, other more widely accepted measures of metastatic burden are not difficult
to perform in future studies. Thus, future studies will be performed to test the usefulness
of a unilateral 4T1-luc2 tumor cell implantation followed by a 20+ day tumor progression
period followed by resection model as a method of reliable induction of lung metastases
with a micrometastatic/circulating tumor cell treatment window.
2.4 9th MAMMARY FAT PAD 4T1-LUC2 METASTASIS MODEL
2.4.1 DETAILED METHODS
Tumor Model
8-12-week-old female BALB/c mice were injected with 2x105 4T1-luc2 cells
suspended in 20 µL PBS into only the right, 4th (9th) mammary fat pads. The target tumor
size for metastasis determined in the previous study was 1500 mm3. Tumors were
measured every 3 days beginning at Day 10 until they reached this size. Once the target
tumor volume was reached (Day 28), IVIS images were obtained and mice were
separated into two groups based on equal average tumor size and metastatic burden while
also maintaining equal average ages between groups. Tumors were resected on Day 28 as
described previously, and i.p. injections of PBS, 2% DMSO by volume containing either
0 mg/kg or 40 mg/kg emodin were administered daily beginning on Day 29. Volume of
injection was calculated based on mouse weight, and ranged from 0.8 mL to 1 mL.
Injections were given until mice died or were sacrificed due to moribunity. Survival
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proportions were tracked until the last mouse was sacrificed (Day 41 since tumor
injection).
IVIS Imaging
BALB/c mice bearing 4T1-luc2 tumors were imaged using the IVIS Spectrum
(PerkinElmer) as described previously in Subsection 2.3 prior to tumor removal, and all
mice were imaged after tumors were resected, to gage the completeness of resection and
presence of metastasis at the time of tumor removal. Photons/second was used to
determine the luminous flux from the tumor cells and adjust for differences in exposure
time.
Statistical Analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Two group
comparison was accomplished using a two tailed Student’s t test. All such comparisons
were performed using GraphPad Prism 5 software (Graphpad Software Inc., San Diego,
CA). Survival data were analyzed using the Mantel-Cox log-rank test. p≤0.05 was
considered statistically significant for all tests.
2.4.2 RESULTS
4T1-luc2 cells metastasize almost exclusively to the lungs
The 4T1-luc2 cells, surprisingly, took two days longer to reach the target volume
for removal (1500 mm3) than the 4T1-luc2-RFP cells did. However, the 4T1-luc2 cells
exhibited earlier metastatic dissemination. ~64% of the mice were found to have overt
lung metastases on IVIS Spectrum imaging 24 h after primary tumor removal, and these
metastases were visible prior to tumor excision when the primary tumor was covered
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during imaging to prevent the much brighter tumor tissue from saturating the detector
(Figure 2.7B).
Emodin increased overall survival in lung metastasis bearing mice
Mice were divided evenly between 40 mg/kg emodin treatment and vehicle
control groups based on tumor volume/radiance and lung field radiance, indicative of
metastatic dissemination prior to tumor resection (Figure 2.8A). There was also no
difference between lung field radiance 48 h after primary tumor removal (Figure 2.8B).
Several of the mice also appeared to have residual primary tumor tissue after surgery.
Emodin and vehicle i.p. injections were given daily until the conclusion of the study,
which was only 13 days after tumor resection. The health of the mice deteriorated much
more rapidly than in previous studies due the presence of advanced disease at the time
treatment was initiated. We found that even this abbreviated course of emodin treatment
led to a statistically significant increase in the median overall survival of the mice by
19% (Figure 2.8C). Additionally, the final 3 emodin-treated mice were sacrificed once
statistical significance was reached due to the fact that they were exhibiting some signs of
labored breathing due to the presence of lung metastases. It is likely, however, that these
mice may have survived a few more days before they each died or became impaired to
the extent requiring sacrifice. All of the mice in both groups were found to have extensive
lung metastasis on necropsy or at sacrifice. This was likely due to their being established
prior to tumor resection and adjuvant therapy.
2.4.3 DISCUSSION
This experiment demonstrated that the 4T1-luc2 cells implanted only into the 9th
mammary fat pad had a more rapid onset of metastasis and exhibited a much more
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specific lung tropism than the 4T1-luc2-RFP cells implanted bilaterally. It is not clear
from this study whether this improvement is due solely to the change in cell line or in
injection location or is affected by both, and knowing this is not crucial for the design of
our final study.
In this study, the 4T1-luc2 cells had already established observable metastases in
a majority of the mice before tumor removal, and several of the mice bore residual tumor
tissue post-surgery. Our goal is to apply emodin treatment to mice bearing only
micrometastases and circulating tumor cells with no local recurrence and no lung
metastases visible on post resection IVIS Spectrum imaging. In order to accomplish this,
mice will be imaged frequently during the course of tumor growth with the tumors
obscured. This should allow for the observation of the first detectable lung metastases
and initiation of emodin treatment when the majority of the mice have either only very
small metastases or circulating tumor cells. More tissue will also be removed around the
primary tumor to ensure clean margins.
We also found that even mortality due to the progression of established lung
metastases can be delayed by emodin treatment at a dose that we have used previously
and have shown to not be directly tumoricidal [103, 118].
2.5 FINAL 4T1-LUC2 METASTATIC RECURRENCE MODEL TEST
2.5.1 DETAILED METHODS
Tumor Model
27 7-week-old, female BALB/c mice were purchased from Jackson Labs, and
were housed at the University of South Carolina Animal Research facility for one week
prior to use in experiments. At 8 weeks of age, all mice were injected with 2x105 4T1-
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luc2 cells (PerkinElmer) suspended in 20 µL PBS into only the 9th mammary fat pad. The
target date for tumor resection was between 20 and 25 days after tumor cell implantation.
Tumors were measured every 3 days beginning at Day 11. Mice were separated into three
groups based on equal average tumor volume measured on the day of tumor resection.
Tumors were resected on Day 23 as described previously, and i.p. injections of PBS, 2%
DMSO by volume containing either 0 mg/kg, 20 mg/kg, or 40 mg/kg emodin were
administered daily beginning on Day 24. Injection volume was calculated based on
mouse weight, and ranged from 0.8 mL to 1 mL. Injections were given daily until the
termination of the study. Three mice from each group with obvious lung metastases one
week after surgery were sacrificed. The remaining mice were sacrificed at 2 weeks post
tumor resection.
IVIS Imaging
BALB/c mice bearing 4T1-luc2 tumors were full-body imaged using the IVIS
Spectrum (PerkinElmer) prior to, 48 h after, and one week after tumor resection as
described in Subsection 2.3. Photons/second was used to determine the luminous flux
from the tumor cells and adjust for differences in exposure time.
The lungs of mice were also imaged ex vivo using the IVIS Spectrum. To do this,
two more solutions of D-luciferin were prepared at 150 µg/mL and 300 µg/mL in
addition to the 15 mg/mL used for i.p. injection. All luciferin solutions were sterile
filtered using 22-µm syringe filters. Mice were injected i.p. with the same volume of 15
mg/mL D-luciferin solution as in full body imaging, but were only allowed 5 min to
recover before being sacrificed. Lungs of the mice were then perfused with the 150
µg/mL D-luciferin solution by cutting the left atrium and injecting the D-luciferin
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solution into the right ventricle. The lungs were then excised and placed in the wells of a
12-well plate containing 1 mL of 300 µg/mL D-luciferin solution and imaged
immediately on the IVIS Spectrum.
Statistical Analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representing a sample group’s behavior. Two group comparison of
means was accomplished using a 2-tailed Student’s t test, and three group comparisons of
means was accomplished using a two tailed ANOVA followed by Tukey multiple
comparisons test. Survival data were analyzed using the Mantel-Cox log-rank test. All
such comparisons were performed using GraphPad Prism 5 software (Graphpad Software
Inc., San Diego, CA). p≤0.05 was considered statistically significant for all tests.
2.5.2 RESULTS
4T1-luc2 cells implanted in the 9th mammary fat pad metastasize efficiently to the lungs
The growth of 4T1-luc2 tumors was very uniform across all mice and across the
three groups prior to resection (Figure 2.9B). Tumor radiance, collected from full body
IVIS Spectrum imaging, and the weights of resected tumors were also very similar
between groups prior to the onset of treatment (Figure 2.9C). Full body IVIS Spectrum
imaging 48 h after tumor resection shows only three, faint metastases in the cohort of 27
mice, two of which appear to be in the lungs (Figure 2.9D). Similar imaging of the mice
at one week post resection shows 11 of the mice now bearing metastases, 10 of which
appear to lie in the lung fields (Figure 2.9E). At this point, none of the mice exhibit local
recurrence. Between all of the groups at the conclusion of the study, 21 out of the 28
mice were found to be bearing lung metastases detectable on ex vivo IVIS or visible at

40

necropsy. In the vehicle control group, eight of the nine mice developed lung metastases,
fulfilling the goal of achieving ≥80% metastasis formation in the absence of adjuvant
treatment (Figure 2.9F).
Two weeks of emodin treatment decreased both metastasis number and metastatic burden
After one week of daily emodin or vehicle treatment, the three mice with the
highest lung field luminous flux from each group on IVIS Spectrum imaging were
sacrificed, and their lungs were imaged ex vivo (Figure 2.10A). Both the full body and ex
vivo lung imaging showed that there were no differences in total radiance between the
selected mice from the three treatment groups (Figure 2.10B). Lungs were then fixed in
4% paraformaldehyde (PFA) for 48 h, imbedded in paraffin, and sectioned. Sections at
200 µm intervals were stained with hematoxylin and eosin (H&E) and metastases were
counted and quantified using ImageJ software. The total metastatic volume per total lung
volume was measured and termed the “metastatic index”. The number of metastases per
lung section area was also quantified. It was found that while there was no statistically
significant difference in the metastatic index or number of metastases per mm2 between
these three groups, there was a trend toward a decreasing number of metastases per unit
lung area with increasing emodin dosage (Figure 2.10C).
The mice receiving two weeks of emodin treatment exhibited a strong decreasing
trend in lung field luminous flux with increasing emodin dose (Figure 2.10D&E). Lung
section metastasis quantification yielded evidence of a significant decrease in both
metastatic index and number of metastases per unit lung section area for the 40 mg/kg
emodin treated group versus vehicle control (Figure 2.10F).
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2.5.3 DISCUSSION
These data show that, though the trials described above, we have developed a
reliable method to mimic the clinically observed phenomenon of metastatic recurrence
from disseminated micrometastases and circulating tumor cells after primary surgical
removal of the tumor. This model allows for the testing of adjuvant therapies for their
effectiveness in slowing or preventing recurrence, which is a much more clinically
relevant therapeutic goal than simply reducing the growth of a primary tumor or limiting
the metastatic spread of a tumor that is allowed to remain in the body long after it would
have been diagnosed and removed. Here this model was used to test emodin, but any
number of adjuvant or neoadjuvant therapies can be screened using this model. It could
also be adapted to humanized mouse models in the future to further increase the clinical
relevance of tested treatment paradigms. The availability of a murine model that
addresses goals relevant to human breast cancer treatment is necessary for effective preclinical screening of proposed therapies.
This final iteration of the model has also demonstrated that emodin can effectively
reduce both metastatic burden and number when administered as an adjuvant therapy.
This is likely due to both the direct effects of emodin on TAMs observed previously in
our lab as well as the interference with tumor-promoting TAM-tumor cell crosstalk [118].
It is likely that other mechanisms may also be at play, and further studies of such
phenomena are ongoing.
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Table 2.1 Antibodies for flow cytometry.
Antibody
CD45 (PE/Cy7)
CD3 (APC/Cy7)
CD8 (FITC)

Product #
103113
100221
100803

Company
Biolegend
Biolegend
Biolegend
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Figure 2.1 10 days of tumor growth was insufficient to achieve an appropriately
high metastatic rate with 4T1-luc2-RFP cells. A, Timeline of this experiment. 7-weekold, female BALB/c mice received 2x105 4T1-luc2-RFP cells, bilaterally, in the 4th pair
of mammary fat pads. Tumors were resected as indicated on the timeline, and treatment
with either 2% DMSO in PBS (vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was
administered i.p. daily for two weeks post surgery, then every other day for two more
weeks. B, Tumor growth was monitored until tumor resection, there were no differences
in measured tumor volume between groups. C, IVIS imaging of mice prior to tumor
removal and lung field radiance. D, IVIS imaging of mice after tumor removal and lung
field radiance. E, IVIS imaging of mice on Day 26 since tumor cell implantation; lung
metastases are visible. F, Percentage of mice in each treatment group to ever develop
metastases. Results are shown as means ± SE (n=9).
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Figure 2.2 Metastases did not occur preferentially in the lungs. A, Percentages of
metastases by location in all groups of mice determined from IVIS imaging.

Figure 2.3 Mice were able to recover from surgery and metastases appeared
quickly. A, Prevalence of metastases (all locations) across all groups.
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Figure 2.4 Emodin treatment showed a decreasing trend in metastatic burden and
an increasing trend in overall survival. A, Lung field IVIS data from Days 9-26 since
tumor cell implantation. Day 21 where mice began to die from their disease is indicated.
B, Percentage of mice bearing metastasis in each treatment group based in IVIS data. C,
Overall survival of each treatment group for the duration of the experiment. D, The final
IVIS image obtained, 48 days since tumor cell implantation. E, Lung CD8+ T cell flow
cytometry result. Results are shown as means ± SE (n=9).
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Figure 2.5 The metastatic tropism of 4T1-luc2-RFP cells following primary tumor
resection is not lung-specific. A, Timeline of this experiment. 8 week-old, female
BALB/c mice received 2x105 4T1-luc2-RFP cells, bilaterally, in the 4th pair of mammary
fat pads. Tumors were resected as indicated on the timeline at 3 time-points in order to
determine the duration of tumor growth necessary for metastatic dissemination. B,
Average tumor volume per group; there were no differences in measured tumor volume
between groups. C, Tumor radiance from IVIS imaging by resection group. D, Average
tumor weights at each removal date. E, IVIS images showing tumor removal and
recurrence over the course of the study. Results are shown as means ± SE (n=5).
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Figure 2.6 Gross lung metastases only developed after 26 days of tumor growth
before resection. A, Lungs of mice remaining alive at the study endpoint (Day 53) with
surface metastases indicated. B, Quantification of lung surface metastases per mouse.
Results are shown as means ± SE (n=3-5).
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Figure 2.7 4T1-luc2 cells metastasize almost exclusively to the lungs. A, Timeline of
this experiment. 8-12 week-old, female BALB/c mice received 2x105 4T1-luc2 cells in
the 4th right (9th) mammary fat pad. Tumors were resected as indicated on the timeline,
and treatment with either 2% DMSO in PBS (vehicle) or 40 mg/kg emodin was
administered i.p. daily for the duration of the study. B, Pre-surgery tumor IVIS image,
and pre- and post-surgery lung field IVIS imaging.
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Figure 2.8 Emodin increased overall survival in lung metastasis bearing mice. A,
Tumor and lung field radiance prior to resection (Day 28); no difference is observed
between treatment groups in either parameter. B, Lung field radiance after tumor
removal, again showing no difference between treatment groups. C, Overall survival of
mice until the termination of the study. Results are shown as means ± SE (n=6-7). *
p<0.05.
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Figure 2.9 4T1-luc2 cells implanted in the 9th mammary fat pad metastasize
efficiently to the lungs. A, Timeline of this experiment. 7 week-old, female BALB/c
mice received 2x105 4T1-luc2 cells in the 4th right (9th) mammary fat pad. Tumors were
resected as indicated on the timeline, and treatment with either 2% DMSO in PBS
(vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was administered i.p. daily for the
duration of the study. B, Average tumor volume per group; there were no differences in
measured tumor volume between groups prior to treatment. C, Pre-surgery IVIS image,
tumor weight, and tumor radiance by group. D, Post-surgery lung field radiance, Day 25.
E, Post-surgery lung field radiance, Day 30. F, Proportions of mice with lung metastases
visible on IVIS at Day 30 since tumor cell implantation. Results are shown as means ±
SE (n=9).
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Figure 2.10 Two weeks of emodin treatment decreased both metastasis number and
metastatic burden. A, Ex vivo IVIS image of lungs from 3 mice per group with the
largest metastases after 1 week of treatment. B, In vivo and ex vivo IVIS data showing no
differences between groups. Results are shown as means ± SE (n=3). C, Quantification of
metastases from serial lung sections from these 3 mice. D, Ex vivo IVIS image of lungs
from remaining mice after 2 weeks of treatment. E. Ex vivo IVIS data from these mice. F,
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Quantification of metastases from the final 6 mice and representative lung section
images. Results are shown as means ± SE (n=6). *p<0.05, **p<0.01.
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CHAPTER 3
EMODIN AS AN AGENT TO PREVENT BREAST CANCER POST-SURGERY
METASTATIC RECURRENCE
3.1 BACKGROUND
Breast cancer is still the second leading cause of cancer-related death among
women worldwide. Triple-negative breast cancer has remained difficult to treat, and
clinical outcomes are very poor, especially if the cancer has metastasized [3]. Our lab has
established that emodin, an anthraquinone derived from herbs used in traditional Chinese
medicine, is capable of modulating macrophage activation and interfering with the tumorpromoting feedback loop between tumor cells and macrophages, leading to decreased
metastatic dissemination and decreased tumor growth [103, 118, 120]. Emodin, like
many other naturally derived compounds, is inexpensive and capable of affecting
multiple pathways simultaneously [121-123]. It has also demonstrated very low toxicity
[104]. There are currently no cancer treatments specifically targeting macrophages or
innate immunity. Thus emodin may prove complementary to other immune therapeutic
strategies, the majority of which are intended to boost adaptive immunity. The generally
immune suppressive tumor microenvironment fostered by M2-like tumor associated
macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells
(Tregs) hampers existing antitumor immunity and decreases the effectiveness of immune
therapeutic strategies. Some therapies meant to address this general immune suppression
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have proven effective in the laboratory setting, but none have yet progressed to clinical
use [124-126].
In order to help bridge this gap, we have performed a study investigating
emodin’s effectiveness as an adjuvant chemotherapy for triple negative breast cancer.
The relative pattern of human breast cancer treatment was mimicked in this murine
model with surgical resection before macrometastases were visible, followed by emodin
treatment and recurrence monitoring. In this model, as is often the case with human
cancer treatment, the primary tumor is removed prior to the initiation of chemotherapy,
therefore the therapy is meant to only affect any residual tumor tissue, either at the
primary sites or disseminated to the circulation or distant organs. However, the immune
suppressive environment engineered by the tumor for its own protection is diminished for
a brief period, but still present following resection, and is still capable of aiding in the
survival of any established or circulating tumor cells and reducing the success of immune
therapeutic strategies [127]. Here we show that through emodin’s direct effects on these
remaining tumor cells and its effects on macrophages, metastatic recurrence of triple
negative breast cancer is significantly degreased, and overall and metastasis-free survival
are both increased. The mechanism for this is at least in part related to the direct and
indirect modulation of cancer cell epithelial to mesenchymal transition (EMT) by
emodin. We show that emodin can directly decrease transforming growth factor-β (TGFβ) production by TAMs which in turn reduces tumor cell EMT. Acting in this way,
emodin can both reduce the ability of circulating and newly arrived cancer cells to
effectively establish metastases and help to counteract the systemic immune suppression
imposed by the primary tumor.
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3.2 DETAILED METHODS
Tumor cell culture and conditioned medium collection
EO771 tumor cells were obtained in 2012 and 4T1 cells were obtained from the
American Type Culture Collection (ATCC) in 2013 and were expanded in high-glucose
Dulbecco’s modified eagle medium DMEM supplemented with 10% fetal bovine serum
(FBS), 100 U/mL penicillin (Sigma-Aldrich Corp.), and 100 µg/mL streptomycin
(Sigma-Aldrich Corp.) in a 37˚C, humidified, 5% CO2 incubator. Tumor conditioned
medium was collected by first culturing tumor cells expanded to 70% or 90% confluence
for EO771 and 4T1 cells, respectively, in T-75 bottles (Corning Inc., Corning, NY).
Medium was then removed, plates were gently rinsed once with phosphate-buffered
saline (PBS), and 10 mL of serum-free DMEM containing penicillin and streptomycin
(P/S) was added. Cells were cultured for 48 h in this medium, which was then collected,
centrifuged at 350 x g for 5 min to remove large cellular debris, and filtered through a 45µm vacuum filter (Corning Inc.). This medium was then concentrated using 3-kD
molecular weight cutoff centrifuge concentrators (Sigma-Aldrich Corp.) to 25X. Aliquots
were stored at -80˚C for later use. To treat macrophages, conditioned medium was diluted
1:5 in fresh serum-free DMEM and termed tumor-conditioned medium (TCM).
Peritoneal macrophage harvesting and conditioned medium collection
Mice were injected intraperitoneally (i.p.) with 4% Brewer thioglycollate at a
volume of 100 µL/g of mouse body weight. Three days later mice were sacrificed and
macrophages were collected by peritoneal lavage using 20 mL ice-cold PBS. Peritoneal
cells were plated in DMEM + 10% FBS + P/S and cultured in a 37˚C, humidified, 5%
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CO2 incubator for 1 h, at which time non-adherent cells were rinsed away. The adherent
macrophages were then cultured overnight in serum-free DMEM before treatment.
Treatment consisted of 24 h in 4T1 or EO771 tumor cell-conditioned medium
(depending on whether macrophages were obtained from BALB/c or C57BL/6 mice,
respectively). This medium was either supplemented with emodin at 25 µM or DMSO as
a vehicle control. After this 24 h treatment, macrophages were rinsed and cultured in
serum-free DMEM for an additional 48 h. This macrophage-conditioned medium was
then collected and used immediately to treat the tumor cell line of the corresponding
background.
Non-contact macrophage/tumor cell co-culture
1x105 4T1 or EO771 tumor cells were seeded in 24-well plates in serum-free
DMEM. 1x105 syngenic murine macrophages, previously treated for 24 h with TCM with
or without 25 µM emodin, were seeded in trans-well inserts with 8-µm-pore polyethylene
terephthalate membranes (Corning Inc.). This non-contact co-culture setup was placed in
a 37C, 5% CO2 incubator for 48 h. At the end of this incubation period, the tumor cells in
the bottom chamber were rinsed with PBS and lysed with Qiazol (Qiagen, Hilden,
Germany) for RNA extraction and qPCR.
Trans-well invasion assay
Tumor cell invasion capacity was tested by determining their ability to migrate
through Matrigel® Basement Membrane Matrix (Corning Inc.). To do this, 100 µL icecold Matrigel was added to the inside of trans-well inserts with 8-µm polyethylene
terephthalate membranes which fit into the wells of 24-well plates (Corning). Matrigelcontaining trans-well inserts were then incubated at 37˚C for 30 min to allow the Matrigel
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to solidify. 300 µL of DMEM + with 10% FBS, as a chemoattractant, or serum-free
DMEM was added to wells of 24-well plates followed by the Matrigel-containing transwell inserts. 1x105 4T1 or MDA-MB-231 breast tumor cells were seeded on top of the
Matrigel inside the trans-well inserts in serum-free DMEM. Prior to this seeding, tumor
cells had been pretreated with either 0.05% DMSO (as vehicle control), 6 ng/mL TGFβ1, 25 µM emodin, 6 ng/mL TGF-β1 + 25 µM emodin, or, for 4T1 cells, conditioned
medium from macrophages treated with either 4T1-conditioned medium, 25 µM emodin,
or both. The base medium for all pretreatments was serum-free DMEM.
Migration assay
4T1 or MDA-MB-231 cells were cultured in DMEM 10% FBS+P/S to confluency
in 12-well plates. A scratch was then made through the layer of cells with a sterile pipette
tip. Various treatment media were applied for 16 h, at which time the amount that the
tumor cells had migrated in to fill the gap was measured using ImageJ software. The
treatment media consisted of serum-free DMEM supplemented with either 0.06% DMSO
(as vehicle control, also included in all other treatments in this list), 25 µM emodin, 6
ng/mL TGFβ1, and 6 ng/mL TGFβ1 + 25 µM emodin. Tumor cells were also treated with
macrophage-conditioned medium from macrophages treated with either 4T1-condioned
medium or 4T1-condiioned medium + 25 µM emodin as described previously.
RNA extraction and quantitative real-time PCR
For RNA extraction, cells were lysed with TRIzol reagent (Thermo Fisher
Scientific, Waltham, MA). RNA was then extracted by precipitation according to the
manufacturer’s protocol. Briefly, 0.5 mL isopropanol was added to the 1 mL TRIzol,
incubated at RT for 10 min, and centrifuged at 12,000 x g at 4˚C for 10 min. Supernatant
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was discarded, and the resulting pellet was washed in 1 mL 75% ethanol, then
centrifuged for 5 min at 7,500 x g at 4˚C. Supernatant was again discarded and the pellet
was allowed to air dry. RNA pellets were resuspended in 20 µL of RNase-free water and
heated at 60˚C for 10 min. RNA concentration was measured using an Evolution 60
spectrophotometer (Thermo Fisher Scientific). cDNA was then synthesized using 1 µg
RNA, or the maximum amount possible if less than 1 µg, using iScript cDNA Synthesis
Kits (Bio-Rad Laboratories, Hercules, CA). qPCR was performed using iQ SYBR Green
Supermix (Bio-Rad Laboratories). All cDNA stocks were diluted 1:25, and 10 µL of the
resulting solution was used for each qPCR reaction. Primers are listed in table 3.1. qPCR
run conditions were 95˚C for 5 min followed by a repeated cycling of 95˚C for 10 sec,
58˚C for 15 sec, and 72˚C for 20 sec. A melt curve was then collected through the
following temperature fluctuations: 95˚C for 10 sec, 65˚C for 5 sec, and terminating
again at 95˚C. All samples were run in duplicate using a Bio-Rad CFX Real Time
thermocycler. The ΔΔCt method was used to determine relative expression.
Western Blotting
For protein extraction, cultured tumor cells were lysed in RIPA buffer (Pierce,
Rockford, IL) supplemented with 1:100 protease inhibitor cocktail and 1:100 phosphatase
inhibitor cocktail (Sigma-Aldrich Corp.). Protein was quantified using the Lowry
method, and loaded into 10% SDS-PAGE precast gels (Bio-Rad Laboratories). Protein
was the transferred onto nitrocellulose membranes (Sigma-Aldrich Corp.). Membranes
were probed with indicated primary antibodies (Cell Signaling Tech. Danvers, MA), then
the corresponding secondary antibodies (Santa Cruz Biotech. Dallas, TX) conjugated to
horseradish peroxidase. Protein was detected using ECL kits (Pierce) and signal
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intensities were quantified using Image-Pro Plus analysis software (Media Cybernetics,
Rockville, MD)
Flow cytometry
Flow cytometry was performed for both in vitro and in vivo experiments. For in
vitro experiments, peritoneal macrophages were removed from plates using Accutase
(Biolegend). Single cell suspensions of 1x106 cells in 100 µL PBS were blocked with
CD16/32 blocking antibodies (Biolegend) at a concentration of 2.5 µg/mL for 10 min at
4˚C. Cells were then stained with anti-CD206 PE for 30 min at 4˚C.
Lymph node cells were dissociated using 70-µm cell strainers (Corning), rinsed,
counted, and 1x106 cells were suspended in 100 µL PBS for staining. Lymph node cells
were blocked with anti-CD16/32 antibodies as described and surface stained with the
following markers for 30 min at 4˚C: anti-CD45 PE-Cy7, anti-CD11c PE, anti-CD3
APC-Cy7, anti-CD4 APC, anti-CD8 FITC, anti-CD69 PE, and anti-CD103 FITC.
Internal staining was performed using a BD Cytofix/Cytoperm Fixation Permeabilization
Kit (BD Biosciences) according to the manufacturer’s instructions. The antibodies used
to stain intracellular antigens were anti-IFNγ PE and anti-FOXP3 PE, each at a
concentration of 4 µg/mL in the manufacturer specified buffer.
All samples were washed twice with PBS after staining and resuspended in 500
µL PBS for flow cytometry. Samples were analyzed on a BD FACS Aria II using FACS
Diva software (BD Biosciences). 10,000 to 100,000 events were collected for each
sample. All antibodies mentioned here were purchased from Biolegend.
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Orthotopic tumor model and surgical resection
7-week-old, female BALB/c mice were housed at the University of South
Carolina Animal Research Facility; all procedures were approved by the Institutional
Animal Care and Use Committee. At 8 weeks of age, 4T1-luc2 cells (PerkinElmer) were
suspended in PBS at a concentration of 1x107 cells/mL and 2x105 cells were implanted
into the 9th mammary fat pad of each mouse as described previously. Tumor size was
monitored and measured every 3-4 days beginning on Day 10 after implantation. The
following equation was used to calculate tumor volume: (short axis)2 x (long axis)/2 ≈
volume. The tumors were removed according to the following procedure on Day 21: each
mouse was anesthetized using an isoflurane vaporizer, and maintained under anesthesia
for the duration of the surgery with the vaporizer set to deliver 2% isoflurane. The
surgical field was cleaned liberally with 70% ethanol and betadine swabs. A 1-2 cm
incision was made medial to the tumor, and the tumor, with as much surrounding fat pad
as possible, was resected. An electrocautery unit was on hand to stop excess bleeding if
necessary. Incisions were closed with stainless steel clips and suture. Mice were allowed
to recover in a cage heated to 30˚C. Immediately following surgery, the three groups of
mice received i.p. injections of PBS with 2% DMSO by volume containing either 0
mg/kg, 20 mg/kg or 40 mg/kg emodin. The volume of these injections was ~800 µL per
mouse. These i.p. injections were administered daily for the next 17 days. On the 17th day
after tumor resection (38th day since tumor cell implantation), the mice were anesthetized
with isoflurane and sacrificed by cervical dislocation. Lungs and lung-draining lymph
nodes were collected for further analysis.
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In vivo IVIS imaging
BALB/c mice bearing 4T1-luc2 tumors were imaged using an IVIS Spectrum
(PerkinElmer). D-luciferin (Sigma-Aldrich Corp.) was dissolved in PBS at a
concentration of 15 mg/mL. Mice received 10 µL of this solution per gram body weight
intraperitoneally (i.p.), were anesthetized using an isoflurane vaporizer, and images were
obtained at 600 nm wavelength 10 min after receiving the D-luciferin injection.
Metastatic recurrence and primary tumor size were monitored using the IVIS Spectrum to
image the luciferase activity in the 4T1-luc2 cells using the same imaging procedure
described here. In vivo IVIS imaging was performed on Days 20, 21, 24, and 30 since
tumor cell implantation.
Ex vivo IVIS imaging
Ex vivo IVIS imaging was intended to generate a more accurate estimate of the
mice with lung macro-metastases than the in vivo imaging of disseminated tumor in
which the mouse’s tissue blocked a great deal of the signal and could render relatively
small metastases undetectable. In order to do this, mice were first injected i.p. with Dluciferin in PBS in the same manner as with in vivo imaging already described. However,
mice were allowed 5 min to recover and ensure D-luciferin perfusion following i.p.
injection. Mice were then anesthetized with isoflurane and sacrificed by cervical
dislocation. Lungs of mice were immediately perfused with a 150 µM solution of Dluciferin in PBS, removed, and placed in a solution of 300 µM D-luciferin for imaging.
All of these solutions were maintained at RT. Lungs were imaged at 600 nm emission
wavelength for 5 sec, then washed with PBS and fixed in 8 mL 4% paraformaldehyde
(PFA).
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Metastasis quantification
Following PFA fixation for 24-48 h at RT, mouse lungs were paraffin imbedded
and sections were cut 5 µm thick at 150 µm intervals. Five such sections were obtained
for each lung pair. These were deparaffinized and stained with hematoxylin and eosin.
Stained slides were imaged at 10X magnification using an EVOS FL Auto 2 System
(Thermo Fisher Scientific). Images were tiled in order to view the entire lung using the
EVOS System software. Size of images was limited such that they did not require
compression to be saved by the EVOS System software, ensuring that pixels represented
equivalent real dimensions on every section. Pixel areas of lung tissue and metastases
were measured for each image by hand using ImageJ software. These pixel values were
converted to mm2 using the conversion factor 1.142 pixels/µm determined by the 10X
objective. The number of metastatic nodules per section was also counted. These values
were used to calculate the following parameters for each lung pair: Metastasis Index =
(metastatic volume)/(total lung volume), and Metastasis Number Index = (number of
metastases per section)/(lung section area).
Statistical analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Three group
comparison of means was accomplished using a one-way ANOVA followed by Tukey
multiple comparisons test, while two group comparison was accomplished using a two
tailed Student’s t test. All such comparisons are performed using GraphPad Prism 5
software (Graphpad Software Inc.). Differences between proportions were determined
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using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for
all tests.
3.3 RESULTS
Adjuvant emodin treatment decreases metastatic recurrence of TNBC after surgical
resection
Given our previous results demonstrating the effects of emodin on macrophageinduced tumor growth and metastatic dissemination, we sought to determine its relevance
in a model of post-surgical breast cancer treatment. Our model of metastatic recurrence
involved implanting 4T1-luc2 cells into the 9th mammary fat pads of mice, then removing
these tumors at a time-point experimentally determined to yield >80% metastatic
recurrence, yet no local recurrence in untreated mice. The metastases occur almost
exclusively in the lungs and develop to a detectable extent within 3 weeks after tumor
resection, again in untreated mice. The timeline and treatment schedule of this model is
intended to biologically parallel that implemented in human breast cancer treatment,
where diagnosis is often quickly followed by surgical resection and adjuvant
chemotherapy (Figure 3.1A). After the implantation of 4T1-luc2 cells, tumors were
allowed to grow for 21 days, and were imaged using an IVIS Spectrum prior to resection
(Figure 3.1B). Tumors were surgically removed on Day 21, immediately followed by
IVIS imaging to confirm that all local tumor tissue had been removed and check for
detectable metastases (Figure 3.1C). There was one detectable lung metastasis in the
DMSO only group, and this mouse was excluded from later quantitative analyses.
Treatment was initiated about 8 h post-surgery and consisted of i.p. injections of PBS +
2% DMSO, 20 mg/kg emodin, or 40 mg/kg emodin. Emodin was suspended in PBS +
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2% DMSO for these injections. Mice were divided into three treatment groups based on
equal average tumor size at resection. This was determined both by tumor radiance
detected on IVIS and resected tumor weight (Figure 3.1D). There were no differences in
calculated tumor volume at any point from when tumor size monitoring began on Day 10
through resection (Figure 3.1D). Metastatic recurrence was tracked by IVIS imaging on
Days 3 and 9 after surgery (Days 24 and 30 since tumor implantation) (Figure 3.1E&F).
From the post-surgery IVIS data, it was apparent that tumor cells were present to a lesser
extent in the lung fields of mice that received emodin treatment. Mice were sacrificed 17
days after tumor resection (38 days since tumor implantation) for analysis of the
metastatic microenvironment and the measurement of lung metastatic burden. First, lungs
were perfused and quickly imaged ex vivo using the IVIS Spectrum, yielding a more
accurate estimate of metastatic burden than similar imaging through the chest wall
(Figure 3.1E&G). Lungs were then fixed and 5 sections were taken at 150 µm intervals
though each lung pair. These were H&E-stained in order to render tumor nodules more
visible, and both the number and size of metastatic nodules were quantified for each
section. These values, as well as the total lung area from each section, were used to
calculate the metastatic index (metastasis volume/total lung volume), the number of
metastases per mm2 of total lung section area, and the average size of each metastasis.
The 40 mg/kg emodin dose decreased the metastatic index, the number of metastases, and
the average size of each metastasis (Figures 3.1H&I). Previous studies of the effect of
emodin had only focused on the primary tumor microenvironment, but here for the first
time, we have shown that emodin, when administered only after the primary tumor had
been surgically removed, is still able to affect the establishment and growth of distant
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metastases. Based on IVIS imaging, emodin treatment during this post-surgery period
could reduce metastatic recurrence at the endpoint of the study to ~64.3% from about
~84.6% in the control-treated group (Figure 3.1J). These results lend further credence to
the possibility that emodin has potential as a therapy for both the prevention and arrested
development of triple negative breast cancer metastasis.
Emodin modulates the immune microenvironment of the metastatic site
To gain a more complete understanding of emodin’s effect on the immune
microenvironment of metastases, lung-draining lymph nodes were collected from the
mice involved in the adjuvant emodin therapy experiment and analyzed via flow
cytometry. This revealed some key differences between mice that received emodin and
those that did not. Chiefly, in both emodin-treated groups (20 mg/kg and 40 mg/kg), there
was a significant decrease in CD4+FOXP3+ regulatory T cells (Figure 3.2A). It has been
shown that M2 macrophage-conditioned medium is capable of inducing FOXP3
expression in naïve human CD4+ T cells [128]. It was further shown that of all the
cytokines released by the M2 macrophages, TGF-β was found to be the one on which
CD4+ T cell FOXP3 induction was crucially dependent. A second key finding is that
there appear to be less migratory DCs in the tumor draining lymph nodes of untreated
mice than those treated with 40 mg/kg emodin (Figure 3.2B). Here migratory DCs are
identified as CD11c+CD103+ cells [129]. Again, a likely contributor to this phenomenon
is TGF-β, as it has been demonstrated that TGF-β1 has been shown to arrest DCs within
tumor tissue and prevent migration to lymph nodes where an adaptive immune response
could be more effectively fostered [130]. Lung sections containing metastases were also
stained for markers of macrophage presence (CD68) and activation phenotype (Ym1).
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Less macrophages were present in and around metastatic nodules in the lung tissue of
mice treated with 40 mg/kg emodin (Figure 3.2C). Ym1+ cells, were also fewer in the
regions around metastatic nodules in both the 20 mg/kg and 40 mg/kg emodin-treated
mice compared to the control, indicating a less M2-like phenotype of macrophage
polarization (Figure 3.2D) [131]. It was also interesting to note the obvious ring of
macrophages surrounding many developing metastasis (Figure 3.2E).
These data show that post-surgical emodin treatment is capable of creating a less
immune suppressed, pro-tumor environment in potential metastatic sites, which in turn
may account for the reduction in metastatic burden. It is likely that this effect is at least in
part due to modulation of macrophage activation at sites of metastasis formation resulting
in a change in the release of cytokines from these macrophages, such as TGF-β, known to
increase the metastatic success rate of tumor cells [132].
Emodin inhibits breast tumor cell EMT through modulating macrophage phenotype and
TGFβ secretion.
Previous work by our lab and others has shown that tumor associated
macrophages (TAMs) secrete TGF-β1, and that this can increase the metastatic and
invasive capabilities of tumor cells through affecting tumor cell epithelial-tomesenchymal transition (EMT) [133, 134]. Based on previous observations from our lab
that emodin suppresses tumor-cell induced M2-like macrophage polarization, an
activation phenotype associated with increased TGF-β1 secretion, we hypothesized that
this may be a mechanism by which emodin was able to decrease the establishment of
distant metastases in our murine breast cancer studies [103, 118]. One of our first steps
was to determine whether or not emodin affected TAM TGF-β1 secretion. In order to do
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this, peritoneal macrophages from BALB/c mice were treated with 4T1-conditioned
medium with or without 25 µM emodin for 24 h. Our previous work has indicated that
this concentration is similar to the serum emodin levels in mice treated with 40 mg/kg
emodin administered i.p. [118] qPCR showed that tumor-conditioned medium treatment
increased TGF-β1 expression, and this was abolished when emodin was added. Emodin
alone had little or no effect on macrophage TGF-β1 expression (Figure 3.3A). To further
confirm this relationship in vitro, conditioned medium was collected from macrophages
treated in the same way and ELISA was performed for TGF-β1. Emodin treatment
suppressed the tumor-conditioned medium-induced increase in TGF-β1 protein release
(Figure 3.3B). It is important to note that this increase in TGF-β1 transcription coincided
with a transcriptional profile indicative of M2-like macrophage polarization.
After demonstrating that emodin has the ability to interfere with TAM TGF-β1
production at physiologically achievable concentrations, it is important to also determine
whether or not this interference could lead to changes in tumor cells which affect
metastatic potential, such as the EMT status of tumor cells. To do this, peritoneal
macrophages from BALB/c and C57BL/6 mice were pretreated with serum-free DMEM
supplemented with tumor-conditioned medium from syngenic tumors with or without 25
µM emodin. Macrophage treatment with 0.05% DMSO in serum-free DMEM was used
as a vehicle control. The macrophages were then co-cultured with syngenic tumor cells
using a trans-well setup such that the two cell populations could not directly contact one
another but shared the same medium (Figure 3.3C). After 24 h of co-culture with
macrophages, qPCR on the tumor cells showed that multiple indicators of EMT, such as
N-cadherin and vimentin, exhibited increased expression in the tumor cells co-cultured
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with macrophages that had been exposed to syngenic tumor conditioned medium only
(Figures 3.3D&E). The addition of emodin to this tumor-conditioned medium restored
tumor cell EMT marker expression back to levels similar to co-culture with controltreated macrophages (Figures 3.3D&E). Other genes indicating a shift from an
epithelial-like to a mesenchymal-like phenotype also exhibited a similar pattern,
including matrix metalloproteinases 2 and 9 (MMP2 and MMP9) and fibronectin
(Figures 3.3D&E). Macrophage pretreatment with emodin alone had varying effects on
the levels of these EMT markers (Figures 3.3D&E). Taken together, these results show
that while tumor cells can condition macrophages to exhibit a more M2-like phenotype
and secrete increased levels of EMT-promoting TGF-β1, the addition of emodin can
counteract both M2-like polarization and TGF-β1 secretion in macrophages. This in turn
leads to an inhibition in TAM-induced EMT in breast tumor cells.
Emodin inhibits TGF-β and tumor-associated macrophage-induced migration and
invasion of tumor cells
In our adjuvant therapy model, the primary tumor is never exposed to emodin, so
the observed differences in metastatic burden must be due to either effects on circulating
tumor cells’ ability to initiate metastases, newly established micrometastases, or the
microenvironment at the metastatic site. An important, enabling trait for the formation of
distant metastases is tumor cell invasion/migration. In order for tumor cells to both
escape the primary tumor, enter the vasculature, and to extravasate once at the metastatic
site, they must have sufficient invasive and migratory potential. This motility is enhanced
by EMT, a prime driver of which is TGF-β1 [135]. As expected, TGF-β1 treatment
drastically increased the migratory capacity of 4T1 cells in a scratch migration assay
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(Figure 3.4A&B). When 25 µM emodin was added to the TGF-β1 treatment, migration
ability was reduced back to control-treated levels. Again, emodin alone had little to no
effect on the tumor cells’ ability to migrate. This experiment was also performed with the
human breast cancer cell line, MDA-MB-231. Emodin again reduced the TGF-β1induced tumor cell migration, but in this case, emodin alone also seemed to reduce the
migration ability of the cells (Figure 3.4B).
In order to more firmly establish the connection between macrophage-released
cytokines and these changes in migration, a similar scratch migration assay was
performed on 4T1 cells treated with various macrophage-conditioned media.
Macrophages were pretreated with either DMSO as vehicle control, 25 µM emodin in
DMSO, 4T1-conditioned medium + DMSO, or 25 µM emodin in DMSO + 4T1condiitoned medium. After this pretreatment, macrophages were washed to remove
emodin and 4T1-conditioned medium then cultured in serum-free DMEM, which was
collected as macrophage-conditioned medium. This was an attempt to isolate to effects of
emodin on the cytokines secreted by the macrophages from the direct effects of emodin
on the tumor cells. The results of this assay showed that the conditioned medium from
macrophages treated with 4T1-conditioned medium drastically increased the migration of
tumor cells, and the addition of emodin decreased migration back to control-treated levels
(Figure 3.4C&D). Pretreatment of macrophages with emodin alone had little effect on
subsequent tumor cell migration.
To further test this signaling loop in another model of tumor cell motility,
Matrigel® invasion assays were performed. These were intended to test the hypothesis
that emodin could affect tumor cells’ ability to move through a network of ECM proteins,
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an attribute closely linked to EMT and crucial for both tumor cells leaving the primary
tumor and establishing themselves as distant metastases. Our results from these
experiments were similar to those from the scratch-migration assays, and indeed were
performed under similar conditions. Again TGF-β1 directly increased tumor cell
invasion, and 25 µM emodin was able to directly decrease this effect back to baseline in
both murine and human breast cancer cell lines (Figure 3.4E&F). Treating tumor cells
with conditioned medium from macrophages that had been exposed to 4T1-conditioned
medium also increased their invasive capacity, and this effect was again reversed by the
addition of emodin to the macrophage pretreatment (Figure 3.4G&H). Taken together
these results show that not only is emodin capable of skewing macrophage activation
phenotype such that less EMT-inducing TGF-β1 is produced, it is also capable of
reducing the EMT-promoting effects of TGF-β1 on tumor cells.
The intent of these in vitro studies is to focus on the potential effects that emodin
may be exhibiting in vivo on the ability of tumor cells to extravasate and establish
themselves in the lungs. Previous intravital imaging studies have shown that one of the
first steps of extravasation involves the extension of structures termed invadopodia
through the endothelium into the extravascular space [136]. These invadopodia are
enriched for proteins such as cortactin, Tks4, and Tks5, and proteases such as MMP9 and
MMP2 [136, 137]. Inhibition of invadopodia-related proteins, such as Tks5 has been
shown to reduce breast tumor progression and metastasis [136, 137]. Given our
observations that emodin is able to both decrease metastatic recurrence when
administered as an adjuvant therapy, in the absence of the primary tumor, and decrease
migration and invasion of tumor cells in response to cytokines including TGF-β1 released
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by tumor-exposed macrophages, it is likely that emodin is affecting tumor cells’ ability to
extravasate and establish metastases in vivo. We have already demonstrated the ability of
emodin to reduce the ability of tumor-exposed macrophages to initiate MMP2 and MMP9
expression in tumor cells (Figure 3.3E&F). We further show that both cortactin and
Tks5 expression are reduced in EO771 tumor cells when exposed to conditioned medium
from macrophages pretreated with both emodin and EO771-condioned medium versus
the tumor-conditioned medium alone, indicating decreased formation of invadopodia-like
structures (Figure 3.3I). In addition to this finding, Emodin was also capable of
significantly decreasing Notch1 expression in EO771 tumor cell/macrophage non-contact
co-culture (Figure 3.3I). It has been shown that macrophages induce the formation of
invadopodia and extravasation of tumor cells via Notch1 signaling [138].
Emodin interferes with both TGF-β canonical and non-canonical signaling in tumor cells
TGF-β binding to its receptors largely results in signaling through two branching
cascades referred to as the canonical and non-canonical signaling pathways. The
canonical pathway occurs largely downstream of a phosphorylated Smad2/3 complex,
while the non-canonical pathways are more broadly branching and have been defined as
all non-Smad TGF-β signaling pathways, including but not limited to MAP kinase
pathways and PI3K/Akt pathways [139]. A number of these non-canonical functions have
been linked to EMT, and we examine several in our efforts to determine where emodin is
interfering in the complex web of TGF-β signaling.
We have shown that emodin decreases TGF-β1 secretion from macrophages
exposed to tumor-conditioned medium and that emodin can interfere with TGF-β1’s
induction of a pro-metastatic tumor cell phenotype. Others have shown that emodin is

75

capable of interfering with TGF-β canonical signaling in human cervical cancer cells
[140], but neither its effects on the canonical nor the non-canonical pathways of TGF-β
signaling in breast cancer have been demonstrated. In order to assess canonical TGF-β
signaling, we determined the level of Smad2/3 phosphorylation, which should increase in
response to TGF-β. We found that the ratio of phosphorylated to total (p/t) Smad2/3 is
increased by TGF-β, as expected, and is decreased by the addition of 25 µM emodin in
both mouse and human breast cancer cell lines (Figure 3.5A-C). Akt is phosphorylated
as a component of non-canonical TGF-β signaling leading to induction of EMT in tumor
cells [141]. The addition of emodin to TGF-β treatment decreased its phosphorylation,
though not to a statistically significant degree (Figure 3.5D). STAT3 signaling has
previously been shown to be required for TGF-β-induced EMT in other tumor models
[142]. Here we show that its phosphorylation in 4T1 cells in increased in response to
TGF-β and decreased back to control levels by the addition of emodin (Figure 3.5D).
Finally the transcription factors Twist and Zeb1, both of which are induced by TGF-β
signaling and are important for EMT in various tumors including breast cancer [143,
144], exhibit decreased expression upon the addition of 25 µM emodin to TGF-β
treatment in 4T1 cells (Figure 3.5E). Thus emodin interferes with many aspects of both
canonical and non-canonical TGF-β signaling pathways in breast tumor cells.
3.4 DISCUSSION
Our data show that adjuvant emodin is capable of preventing metastatic
recurrence and slowing the progression of existing metastatic disease in a murine model
of triple-negative breast cancer. Emodin reduced both the size and number of metastases
and increased overall and recurrence-free survival when administered shortly after tumor
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resection in mice not yet presenting with detectable lung metastases. It was also capable
of eliciting changes in the frequency of Tregs (CD4+FOXP3+) and migratory DCs
(CD11c+CD103+) in lung-draining lymph nodes, both of which have been linked to
decreased TGF-β1 signaling. Further investigation showed that indeed emodin treatment
was capable of reducing TAM TGF-β1 production, due at least in part to its ability to
decrease macrophage M2-like polarization. Macrophages pulsed with tumor-conditioned
medium increased tumor cell migration and invasion as well as markers of EMT: all
parameters linked to improvements in the ability of tumor cells to establish metastases.
When emodin was added to this macrophage pretreatment, all three of these phenotypic
markers were significantly decreased, indicating that the changes elicited by emodin
treatment in macrophage cytokine release were capable of imparting less metastatic
tumor cells. In addition to acting through macrophages, emodin also exhibited direct
effects on tumor cell response to TGF-β1. Treatment of tumor cells with TGF-β1
increased marker of EMT, migration, and extracellular matrix invasion as expected, and
addition of emodin again restored tumor cell phenotype to near baseline. It has recently
been discovered that emodin is capable of down-regulating TGF-β signaling in pancreatic
and cervical cancer cells, but its effect on this pathway in breast tumor cells has not been
investigated [140, 145]. Further investigation showed that emodin was able to interfere
with both the canonical and non-canonical pathways of TGF-β1 signaling in several
breast tumor cell lines. Thus emodin is capable of not only reducing TGF-β1 secretion
from TAMs, it also reduces tumor cell response to TGF-β1 by inhibiting its signaling
cascades. These effects combine to render tumor cells much less capable of establishing
distant metastases.
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The majority of literature focused on the effects of emodin on cancer describes
only its direct effects on tumor cell viability or phenotype [98, 146]. Our lab has
previously detailed emodin’s interference with the cross-talk between tumor cells and
macrophages. This feedback loop leads to the promotion of tumor growth and immune
suppression [118]. Furthermore, the concentrations of emodin found to be tumoricidal
were not achievable in serum in our murine models [103]. There have also been a number
of studies in recent years showing that emodin is capable of interfering with TGF-β1
signaling in several cell types, including a few tumors, though results of these studies are
mixed [7, 140, 145]. Some show that emodin has no effect on TGF-β signaling [147]. A
single study has shown that emodin is capable of decreasing tumor cell migration and
invasion as well as MMP-2 and MMP-9 secretion in MDA-MB-231 human breast cancer
cells. This study also demonstrated that emodin treatment decreased lung metastasis in
athymic mice implanted with MDA-MB-231 cells [148]. By employing athymic mice,
this study was able to determine the in vivo effects of emodin on a model of human breast
cancer, but the resulting picture is incomplete as immune cell interaction with tumor cells
is crucial for tumor growth and metastasis, and is certainly important for human cancer
patients. Our findings that emodin affects the production of TGF-β by TAMs, thus also
indirectly reduces metastatic capacity, are novel. An in vitro-only study has shown that
emodin can interfere with TGF-β signaling from the fibroblasts collected from patients
with triple-negative breast cancer and a human breast cancer cell line, BT20 [132]. This
study found that pretreating the isolated fibroblasts with emodin inhibited BT-20 cell
EMT in a direct co-culture system. This direct co-culture model, however, does not limit
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the interactions between fibroblasts and tumor cells to only soluble mediators. Our
indirect co-culture model simply and effectively enforces this limitation.
The major novelty of this study is the implementation of emodin as an adjuvant
therapy in a model biologically mimicking the pattern of human breast cancer treatment.
Showing that emodin is capable of decreasing metastatic recurrence when the primary
tumor has been removed prior to treatment is valuable knowledge that bolsters emodin’s
translational potential.
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Table 3.1 Antibodies for flow cytometry
Antibody
CD45 (PE-Cy7)
CD3 (APC-Cy7)
CD4 (APC)
CD8 (FITC)
CD69 (PE)
IFNγ (PE)
FoxP3 (PE)
CD11c (APC)
CD103 (PE)

Product #
103113
100221
100411
100803
104507
505807
126403
117309
121413

Company
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

Table 3.2 Antibodies for Western Blot/Immunohistochemistry
Antibody
Rb-α-Ym1
Gt-α-rb Alexa Fluor 488
t-SMAD2/3
p-SMAD2/3
t-STAT3
p-STAT3
t-Akt
p-Akt
Zeb1
Twist
Actin
Gt-α-rb IgG HRP
conjugate

Procedure
IHC
IHC
Western
Western
Western
Western
Western
Western
Western
Western
Western
Western

Product #
60130
A11008
5678S
8828S
12640S
9145S
4691S
4060S
sc-515797
sc-81417
A2066
12-348

Company
Stemcell
Invitrogen
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Santa Cruz
Santa Cruz
Sigma-Aldrich
Millipore

Table 3.3 Primers for RT-qPCR
Primer
18s
Arg1
TGFβ
N-Cadherin

Forward
CGCGTTTCTATTTTGTTGGT
TGAACAGGCTGTATTAGCCA
ACA
CGCAACAACGCCATCTATGA
GGGACAGGAACACTGCAAAT
80

Reverse
AGTCGGCATCGTTTATGGTC
AGCACCCTCAACCCAAAGTG
ACCAAGGTAACGCCAGGAAT
CGGTTGATGGTCCAGTTTCT

Vimentin
MMP2
MMP9
Fibronectin
Cortactin
Tks5
Notch1

ATGCTTCTCTGGCACGTCTT
ACACTGGGACCTGTCACTCC
CATTCGCGTGGATAAGGAGT
TTAAGCTCACATGCCAGTGC
GCCACTATCAAGCAGAGG
AGGAGGCTGAGGAGAATC
AAGTGGACATTGACGAGT
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AGCCACGCTTTCATACTGCT
GCGAAGAACACAGCCTTCTC
ACCTGGTTCACCTCATGGTC
TCGTCATAGCACGTTGCTTC
CCAGCCATCGTCAATCAT
ATGCTTGTCACCTGAACC
TGAGGCATAAGCAGAGTTA
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Figure 3.1 Adjuvant emodin treatment decreases metastatic recurrence of TNBC
after surgical resection. A, Timeline of this experiment. 7 week-old, female BALB/c
mice received 2x105 4T1-luc2 cells in the 4th right (9th) mammary fat pad. Tumors were
resected as indicated on the timeline, and treatment with either 2% DMSO in PBS
(vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was administered i.p. daily for the
duration of the study beginning on the same day that tumors were resected. B, IVIS
image of tumors prior to resection. C, IVIS image of mice immediately following tumor
resection. D, Tumor weight at resection, tumor radiance from IVIS image in B, and tumor
growth until resection; no differences between groups are apparent. E, Day 24 and Day
30 lung field radiance from IVIS imaging and Day 38 IVIS radiance from lungs imaged
ex vivo. F, IVIS image from Day 30 showing lung metastases in multiple mice. G, Ex
vivo lung IVIS image on Day 38. H, Representative lung sections with metastases
identified. I, Quantification of lung metastases from serial sections. J, Prevalence of gross
lung metastases from IVIS data at the conclusion of the experiment. Results are shown as
means ± SE (n=13-14). *p<0.05, **p<0.01, ***p<0.005.
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Figure 3.2 Emodin modulates the immune microenvironment of the metastatic site.
A, Representative flow cytometry result and quantification of Tregs in lung-draining
lymph nodes. B, Representative flow cytometry result and quantification of migratory
DCs in lung-draining lymph nodes. C, Quantification and representative
immunofluorescence staining of Ym1+ cells in lung metastases; scale bar = 50 µm. D,
Ym1 staining showing M2 macrophages aggregating in the peripheral area of the lung
metastases; scale bar = 100 µm. E, Quantification of activated CD8+ T cells in lungdraining lymph nodes from flow cytometry. Results are shown as means ± SE (n=13-14).
*p<0.05, **p<0.01.
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Figure 3.3 Emodin inhibits breast tumor cell EMT through modulating macrophage
phenotype and TGFβ secretion. A, qPCR of TGF-β1 in macrophages treated with
EO771-conditioned medium, emodin (25 µM), or both. B, ELISA for TGF-β1 in
supernatants from macrophages treated as in A. C, Non-contact macrophage/tumor cell
co-culture schematic. D, qPCR of 4T1 cells after 24 h of non-contact co-culture with
macrophages pretreated as shown for EMT-related genes. E, qPCR of EO771 cells after
24 h of non-contact co-culture with macrophages pretreated as shown for EMT-related
genes. Results are shown as means ± SE (n=3). *p<0.05, **p<0.01, ***p<0.005.
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Figure 3.4 Emodin inhibits TGF-β and tumor-associated macrophage-induced
migration and invasion of tumor cells. A, Representative images of 4T1 cell migration
during treatment with TGF-β1 (5 ng/mL), emodin (25 µM), or both. B, Quantification of
4T1 and MDA-MB-231 cell migration when treated as in A. Migration index = (width
before migration-width after migration)/width before migration, normalized to vehicle
control (DMSO). C, Representative images of 4T1 cell migration during treatment with
conditioned medium from macrophages pretreated as shown. D, Quantification of 4T1
cell migration treated as in C. E, Representative images of 4T1 cell Matrigel® invasion
during treatment with TGF-β1 (5 ng/mL), emodin (25 µM), or both. F, Quantification of
4T1 and MDA-MB-231 cell migration treated as in E. G, Representative images of 4T1
cell Matrigel® invasion during treatment with conditioned medium from macrophages
pretreated as shown. H, Quantification of G. I, qPCR of invadopodia-related genes from
EO771 tumor cells treated with conditioned media from macrophages pretreated as
shown. Results are shown as means ± SE (n=3). *p<0.05, **p<0.01, ***p<0.005.
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Figure 3.5 Emodin interferes with both TGF-β canonical and non-canonical
signaling in tumor cells. 4T1(A), EO771 (B), and MDA-MB-231 cells (C) were treated
with TGF-β1 (5 ng/mL) with or without emodin (25 µM) for 1 h; Smad2/3 and pSmad2/3 protein levels were detected by western blot. D, 4T1 cells were treated as in AC; protein levels of STAT3, p-STAT3, Akt, and p-Akt were detected by western blot. E,
4T1 cells were treated with TGF-β1 (5 ng/mL) with or without emodin (25 µM) for 24 h;
protein levels of Twist and Zeb1 were detected by western blot. Results are shown as
means ± SE (n=3). *p<0.05, **p<0.01, ***p<0.005.
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CHAPTER 4
GENERATION OF A MICRORNA-155 TRANSGENIC MOUSE MODEL
4.1 BACKGROUND
MicroRNA-155 (miR155) is processed into its active form from its primary
transcript, the B cell Integration Cluster (BIC), located on chromosome 21 in humans
[149]. BIC is so named due to its initial discovery as a transcript present in chicken B cell
lymphomas induced by integration of the avian leukosis virus [150]. Sometime later it
was appreciated that pre-miR155 was transcribed from the BIC region in chickens and
was similarly expressed in humans. In fact, miR155 is highly conserved between species
and orthologs have been identified in many species including the evolutionarily ancient
Ciona intestinalis. This early appearance and relatively unaltered maintenance of miR155
in the evolutionary tree also seem to coincide with the development of innate and
adaptive immunity. C. intestinalis possesses a complex innate immune system and some
degree of adaptive immunity through antigen receptor rearrangement [151, 152]. Tied to
this and the initial discovery of the BIC locus in relation to abnormal, virally-induced B
cell expansion, a number of studies have demonstrated the importance of miR155 for
many immune processes and for antitumor immunity, specifically, in several cell types
[153]. BIC, and subsequently miR155, overexpression has been observed in human
Hodgkin’s and diffuse large B cell lymphomas [154-157]. Transgenic mice, engineered
to overexpress miR155 specifically in B cells, exhibit abnormally enhanced pre-B cell
proliferation which develops into B cell lymphoma [158]. It is not clear where enhanced
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miR155 expression falls in the pathogenesis of human B cell lymphomas, but this murine
study at least lends some credence to the possibility of a causative relationship. In
addition to mounting evidence demonstrating a connection between B cell development
and proliferation and miR155, it has also been shown that miR155 deficiency in B cells
reduced both IgM and IgG antibody production in response to Salmonella infection [159,
160]. In addition to this finding, other studies have shown decreased number and size of
lymph node germinal centers in miR155-deficient mice [161-163].
miR155 transcription is physiologically induced in both B and T cell activation
[157, 164, 165]. There have been many studies detailing mechanisms of miR155 activity
in T cell populations. Tumor-infiltrating CD8+ and CD4+ T cells have been shown to
require miR155 for proper IFNγ expression and tumoricidal activity [166].
Overexpression of miR155 in CD4+ T cells has also been shown to promote in vitro Th1
cell differentiation [167], but proliferation was not found to be different between wildtype and miR155-deficient CD4+ T cells in an in vivo murine model of antigen-dependent
T cell activation [160]. Notably, miR155 can directly target SOCS1, a JAK/STAT
inhibitor, Ptpn2, a STAT5 inhibitor, and SHIP1, a PI3K/AKT inhibitor, thus increasing
the activity of these three pathways [168-170]. Due to these regulatory pathways,
increased T cell miR155 expression led to enhanced T cell survival and antitumor activity
in murine models of melanoma. The role of miR155 in Tregs has been shown to involve
similar pathways, but to a different immunologic effect. It was observed that miR155 was
inhibited by the STAT5 pathway in response to CD69 deficiency, which in turn ked to
increased SOCS1 expression and impairment of Treg development [171]. Interestingly
this study places STAT5 upstream of miR155 in Tregs, while the previously described
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studies place it downstream [168-170]. It may be the case that both of these relationships
are present simultaneously in both cell types, creating a negative feedback loop on
miR155 activity. Other studies have also reported Treg dependence on miR155
expression for proliferative capacity, but also that the miR155-dependent reduction in
total Treg burden did not correspond to a measurable decrease in their immune
suppressive activity [172, 173]. All of the studies described thus far were performed in
mice, but it has also been found that miR155 in human dermal lymphatic endothelial cells
(HDLECs) suppresses PD-L1 expression induced by TNFα and IFNγ [174]. Indeed
miR155 is also the most highly up-regulated microRNA in HDLECs responding to TNFα
and IFNγ; in this case, naturally dampening the increase in PD-L1 expression [174].
In cells of monocytic lineage, miR155 has been shown to play both positive and
negative roles in controlling the mammalian immune response [165, 175-177]. The
immunosuppressive functions of myeloid-derived suppressor cells (MDSCs) have been
shown to be both increased and decreased by miR155 in murine models of lung cancer
and melanoma[178, 179]. miR155 signaling has also been implicated in the activities of
monocytes, macrophages, and DCs [180-183]. Direct targeting of arginase-2 (Arg2) by
miR155 in DCs has been linked to increasing the extracellular availability of arginase,
facilitating proper DC-induced T cell activation [184]. Our lab and others have
previously shown that miR155 is a key regulator of DC function, and that its decreased
expression in DCs leads to decreased migration and chemotaxis as well as generalized
depression of maturation and subsequent T cell activation [7, 184-186]. Our studies
uncovered a correlation between CCR7 expression, important for DC migration, and
miR155 in a murine orthotopic breast tumor model. We demonstrated that a potential
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mechanism for miR155’s regulation of CCR7 expression is through directly targeting
Jarid2, which in turn recruits PRC2, a component protein of a complex with histone
methyltransferase activity. PRC2 represses genes primarily by trimethlyating histone H3
at lysine 27 (H3K27me3), and we found enriched H3K27 at the CCR7 promoter in
miR155-/- BMDCs [105]. Unsurprisingly, SHIP1, also shown to be an important target of
miR155 in T cells, has been revealed to be similarly influenced in DCs. In a model of
DC-induced autoimmunity, miR155-/- DCs pulsed with self-antigen and matured with
toll-like receptor (TLR) ligands ex vivo did not bring about a break in self-tolerance,
while wild-type DCs treated in the same manner did, and DCs overexpressing miR155
did so even without TLR-ligand assisted maturation. SHIP1 expression was increased in
miR155-/- DCs, and SHIP1 knockout in DCs allowed for the induction of autoimmunity
in the absence of TLR ligand stimulation, similar to what was achieved with miR155overexpressed DCs [187]. Studies of human DCs differentiated from peripheral blood
monocytes have also focused on the role of miR155. IL-12p70 has been shown to
correlate with miR155 expression level, and maturation of monocyte-derived DCs has
been associated with increased miR155 expression [173, 185].
Only one of these studies used a transgenic miR155 overexpression model [187].
The miR155-transgenic mice in this study were generated by crossing mice containing a
Rosa26 knock-in of the miR155/bic gene preceded by a stop codon with mice expressing
Cre recombinase under the control of the CD11c promoter. Generating transgenic mice
using this method requires continued crossing and genotyping to verify that both the
transgene and Cre recombinase are expressed in the same mouse. Given that these mice
were used to generate bone marrow-derived dendritic cells and not directly for in vivo
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experiments, this CD11c specificity does not seem necessary. Our model globally
overexpresses miR155 at a stable level, therefore removing the additional steps of
crossing and genotyping when generating BMDCs for in vitro studies or adoptive
transfer.
However, the majority of studies seeking to investigate the effects of increased
miR155 expression achieve this by viral transfection. DCs are notoriously difficult to
successfully transfect, and successful infection rates are often low [188]. To reliably
study the effects of augmented miR155 expression, a stable, transgenic overexpression
model could prove very useful. We have developed and validated such a model and
demonstrated the effects of total immune system miR155 overexpression in a murine
orthotopic breast tumor model. Detection of the presence of the transgene as well as
increased expression of mature miR155 in bone marrow, bone marrow-derived DCs
(BMDCs), peritoneal macrophages, and genotyping tail clips confirm that the transgene
is actively transcribed and processed. Transplantation of miR155 transgenic (miR155tg)
bone marrow into wild-type mice later implanted with breast tumor cells confirmed that
the net effect of increased global immune system miR155 leads to more effective
antitumor immunity and prevention of metastatic dissemination.
4.2 DETAILED METHODS
Generation and validation of a miR155 transgenic mouse model
A DNA fragment consisting of a CMV promoter, the mouse Bic sequence, and a
SV40 late polyadenylation signal sequence was used for generation of miR155 transgenic
mice by microinjection. Of the 90 pups implanted with the DNA fragment, four were
found to be positive for the transgene following PCR screening. qPCR of tail clips from
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these four mice further showed that only one of them was obviously producing mature
miR155. Every pup from this single founder’s line was genotyped using PCR and
assessed for overexpression of mature miR155 using qPCR until six generations of mice
were produced.
Genotyping PCR
3 mm tail clips were obtained from 4 week-old pups. 6 wild-type tail clips were
also obtained as age-matched controls for genotyping and qPCR; 3 male, 3 female. Half
of each piece of tissue was used for end-point PCR genotyping and half was used for
qPCR. Tail clips were incubated in 150 µL DirectPCR (Tail) solution (Viagen Biotech
Inc., Los Angeles, CA) containing 2 µL Proteinase K (Viagen Biotech Inc.) at 55˚C in a
shaking water bath overnight. The digestion was terminated by 1 h incubation at 85˚C.
Resulting lysate was then centrifuged at 17,000 x g for 1 min. 3 µL of the supernatant
was taken and mixed with 10 µL 2X green master mix (Promega Corp., Madison, WI),
0.1 µL of both the forward and reverse primer, and 6.8 µL of water to bring the final
reaction volume to 20 µL. PCR amplification was done as follows: 5 min at 94˚C
followed by 36 cycles of 30 s at 94˚C for denaturation, 1 min at 60˚C for annealing, and 1
min at 72˚C for extension. The last cycle was followed by 3 min at 72˚C additional
extension. Primers are listed in table 4.1. 10 µL of each resulting solution and a 100 bp
ladder (Bioline, London, England) were loaded into separate wells of a 1% agarose gel
containing 6 µL ethidium bromide per gram agarose and run for 50 min at 120V, after
which the gel was imaged using a GelDoc XR+ Imaging System (Bio-Rad Laboratories)
for a band at ~215bp.
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Total RNA extraction and quantitative real-time PCR
Tissue/cells were lysed in 700 µL qiazol lysis reagent (Qiagen) and tissue samples
were homogenized. Samples were stored at -80˚C if RNA extraction was not performed
immediately. RNA was extracted using miRNeasy Mini Kits (Qiagen) to also ensure
collection of micro-RNAs. cDNA was then synthesized using 1 µg RNA, or the
maximum amount possible if less than 1 µg, using miScript II RT Kits (Qiagen). RNA
concentration was measured using an Evolution 60 spectrophotometer (Thermo Fisher
Scientific). qPCR was performed using miScript SYBR® Green PCR Kits (Qiagen). All
cDNA stocks were diluted 1:50, and 2 µL of the resulting solution was used for each
qPCR reaction. Primers are listed in table 4.1. qPCR run conditions were 95˚C for 15 min
followed by a repeated cycling of 94˚C for 15 s, 55˚C for 30 s, and 70˚C for 30 s. A melt
curve was then collected through the following temperature fluctuations: 95˚C for 10 s,
65˚C for 5 s, and terminating again at 95˚C. All samples were run in duplicate using a
Bio-Rad CFX Real Time thermocycler. The ΔΔCt method was used to determine relative
expression.
Peritoneal macrophage collection
Brewer’s thioglycollate was prepared at a concentration of 4% and injected i.p.
into mice at a volume of 100 µL per gram mouse weight. Three days after thioglycollate
injection mice were sacrificed and macrophages were obtained by peritoneal lavage with
20 mL PBS. Cells were resuspended and plated in DMEM 10% FBS P/S, cultured for 1
h. Non-adherent cells were then rinsed away with serum-free DMEM; adherent cells
were cultured overnight in serum-free DMEM before being rinsed twice with PBS and
lysed for RNA extraction and qPCR.
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Bone marrow derived dendritic cell differentiation
4-12 week old mice (wild-type C57Bl/6 or miR155tg) were anaesthetized with
isoflurane and sacrificed by cervical dislocation. Hind legs were removed, dipped in 70%
ethanol, and placed in PBS on ice. Femurs and tibiae were cleaned and disarticulated in a
cell culture hood on ice. Epiphyses were removed from diaphyses and rinsed with
complete RPMI (RPMI-1640, 10% heat-inactivated FBS, P/S, and BME) to remove the
bone marrow. Bone marrow was then resuspended in 1 mL RBC Lysing Buffer (SigmaAldrich Corp.) per mouse and gently disrupted by pipetting for 1 min. Lysing buffer was
then diluted with 20 mL RT PBS, centrifuged to pellet and resuspended in complete
RPMI for counting. Bone marrow cells were plated in 10-cm tissue culture-treated,
polystyrene dishes at a density of 3x106 cells/mL in 10 mL complete RPMI supplemented
with 20 ng/mL recombinant murine GM-CSF (Peprotech, Rocky Hill, NJ) and 20 ng/mL
recombinant murine IL-4 (Peprotech) (DC medium) and cultured at 37˚C, 5% CO2
incubator. 10 mL additional DC medium was added on Day 3, and immature,
differentiated DCs were collected on Day 7.
Bone marrow transplantation
6-week-old, female C57Bl/6 wild-type mice were purchased from Jackson Labs
and housed at the University of South Carolina Animal Research Facility. Procedures
were approved by the Institutional Animal Care and Use Committee. Mice were treated
with Neomycin and polymyxin B, administered in drinking water at concentrations of
100 mg/L and 5x105U/L, respectively, for two weeks prior to irradiation and bone
marrow transplantation. Mice were exposed to a dose of 950 rad to ablate existing bone
marrow cells. Donor bone marrow cells (wild-type or miR155tg) were prepared at a
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concentration of 10x106 cells/mL in PBS by rinsing femurs and tibiae followed by RBC
lysing buffer as described previously. 100 µL of appropriate genotype donor bone
marrow cell suspension was injected retro-orbitally into each mouse 6 h after irradiation.
Mice were then maintained on neomycin/polymyxin B-containing water for two
additional weeks after bone marrow transplantation. At sacrifice bone marrow was
collected from all mice and both end-point PCR and qPCR were performed as described
previously to confirm that the transgene was present in the bone marrow and that miR155
was overexpressed.
Tumor model
Four weeks after bone marrow transplantation, the recipient mice were inoculated
with breast cancer cells. 0.2x106 EO771 cells were implanted into the 4th and 9th
mammary fat pads. Tumors were measured using calipers every 3-5 days beginning on
Day 14 when the majority of tumors were obviously palpable. Tumor volume was
calculated using the following formula: (short axis)2 x (long axis)/2 ≈ volume. Mice were
sacrificed 37 days after tumor implantation, and tumors, lungs, blood, spleens, and
tumor-draining lymph nodes were collected.
Lung metastatic burden determination
Lungs were perfused with PBS, then fixed for 24 to 48 h in 10 mL 4%
paraformaldehyde. Fixed lung were imbedded in paraffin and sectioned at 5 µm thickness
at 150 µm intervals. 5 levels were obtained at this spacing from each pair of lungs.
Sections were mounted, de-paraffinized, and H&E stained. Stained sections were then
imaged at 10X magnification using an EVOS FL Auto 2 System (Thermo Fisher
Scientific). Images were tiled in order to view the entire lung using the EVOS System
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software. Size of images were limited such that they did not require compression to be
saved by the EVOS System software, ensuring that pixels represented equivalent real
dimensions on every section. Pixel areas of lung tissue and metastases were measured for
each image by hand using ImageJ software. These pixel values were converted to mm2
using the conversion factor 1.142 pixels/µm determined by the 10X objective. The
number of metastatic nodules per section was also counted. These values were used to
calculate the following parameters for each lung pair: 1) metastatic burden = (metastatic
volume)/(total lung volume), 2) (number of metastases per section)/(lung section area).
Flow cytometry
Tumor tissue, spleens, and tumor-draining lymph nodes were collected from mice
and single cell suspensions of these tissues were analyzed using flow cytometry. Tumors
were chopped into <1 mm3 fragments and enzymatically digested in the following
mixture: 20 mg Collagenase IV (Worthington Biochemical Corp.), 10 µg Hyaluronidase
(Sigma-Aldrich Corp.), and 100 µg DNase 1 (Sigma-Aldrich Corp.) in 5 mL RPMI-1640
medium supplemented with P/S. Digestion took place in a 37˚C water bath for 1 h during.
During this time, the mixture was agitated every 15 min by pipetting or vigorous shaking.
The mixture was then further disrupted using an 18 gauge needle and 10-mL syringe until
most visible fragments were broken up. The mixture was then placed back at 37˚C for 15
more min of digestion. After this final incubation, add 20 mL RT or ice-cold PBS to each
tube to stop digestion. Cells were thoroughly rinsed to remove all digestion enzyme. Red
blood cells were lysed using RBC lysing buffer (Sigma-Aldrich Corp.), 3 mL for 1 min at
RT with gentle pipetting. This was then diluted with 20 mL PBS and passed through a
70-µm strainer, then suspended in PBS and counted. Lymph nodes and spleens were
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mechanically dissociated and passed through a 70-µm strainer. Spleen cells were then
treated with 1 mL RBC lysing buffer for 1 min at RT with gentle pipetting. Both
splenocytes and lymphocytes were then rinsed, resuspended in PBS and counted. Blood
was collected in 1.5 mL Eppendorf tubes containing 12 µL of 0.5-M EDTA to prevent
clotting. 100 µL of each blood sample was collected for treatment with 1 mL RBC lysing
buffer as described previously, rinsed with PBS and counted.
Fc receptors were blocked with anti-CD16/32 antibodies (BD Biosciences, San
Jose, CA) for 10 min at 4˚C. Cells from the various tissues collected were then stained for
the following surface markers: CD45, CD3, CD4, CD8, CD11c, MHCII, CD40, CD80,
CD86, CCR7, CD11b, Ly6C, and CXCL1 (BD Biosciences, San Jose, CA) in 100 µL
PBS for 30 min at 4˚C. Internal staining was performed for IFNγ (BD Biosciences) using
eBioscience Cell Stimulation Cocktail (Thermo Fisher Scientific) followed by BD
fixation and permeabilization treatment per manufacturer protocols. All samples were
rinsed with PBS twice before being analyzed using a BD FACS Aria II flow cytometer
and CXP software version 2.2 (BD Biosciences). Data were collected for 1x104 to 1x106
cells per sample depending on the rarity of the population being analyzed.
Statistical analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Two group
comparison of means was accomplished using a 2-tailed Student’s t test. All such
comparisons were performed using GraphPad Prism 5 software (Graphpad Software
Inc.). p≤0.05 was considered statistically significant for all tests.
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4.3 RESULTS
The miR155-containing transgene is present, expressed, and functional in one founder
Previous studies in our lab have shown that total body miR155-/- increased breast
tumor growth and metastasis, largely though hampering the immune stimulatory abilities
of DCs [105]. Administration of a miR155-/- DC-based vaccine was also carried out in an
orthotopic model of murine breast cancer, which was less effective that a wild-type DCbased vaccine at stimulating an antitumor immune response. We next aim to investigate
whether increasing immune cell miR155 expression could represent a potential
therapeutic strategy for breast cancer, setting the stage for possible future testing of a
miR155-overexpressed DC-based vaccine. In order to produce a model stably
overexpressing miR155, whole-body transgenic mice were generated. The transgene we
designed is under the control of the cytomegalovirus (CMV) promoter for constitutive
expression, though the microRNA will likely be processed into its active form to varying
degrees in different cell populations. Four founder mice (3 male, 1 female) successfully
integrated the transgene into their DNA. Through qPCR on tissue samples from these
founders as well as transgene-positive offspring, it was determined that only one of the
male founders functionally overexpressed miR155, so this line was bred and expanded.
All transgene-positive offspring from this line were found to overexpress miR155
(Figure 4.1A). One of the transgene-positive F1 mice was sacrificed; peritoneal
macrophages and bone marrow-derived DCs were obtained from this mouse as well as an
age and gender-matched C57BL/6 wild-type control mouse (Figure 4.1B-D). It was
revealed that miR155 was also overexpressed in these two immune cell types, and,
unsurprisingly, that baseline miR155 expression was higher in both of these cell types
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than it was in the ear tissue obtained for genotyping. The expression levels of a few other
genes were also determined in order to more convincingly establish that more functional
miR155 was indeed present in the transgenic DCs. SOCS1 and CEBPβ are known to be
direct targets of miR155, and thus their expression levels should be reduced in the
miR155tg cells. Our previous work detailed a regulatory pathway by which CCR7
expression is indirectly increased by miR155, thus it would be expected to be more
highly expressed in the miR155tg DCs. These three genes do appear to reflect a pattern
indicative of the effect of increased functional miR155 (Figure 4.1E). These results
suggest that our model would yield stable, functional miR155 overexpression in immune
cells that could be used in subsequent studies.
Bone marrow cell miR155 overexpression reduces breast tumor growth and lung
metastatic burden
In order to further test both the stable presence and the effects of transgenic
overexpression of miR155, a bone marrow transplant study was performed. There is an
ever-increasing body of work demonstrating that manipulation of miR155 expression
levels leads to altered activity in many immune cell populations. Our previous work using
whole-body miR155-/- mice showed that miR155 was important for a number of
pathways governing the antitumor immune response in DCs, which led to increased
breast tumor growth and progression. Bone marrow transplantation using either C57BL/6
wild-type or miR155tg donor tissue and wild type recipients was performed and mice
were allowed four weeks after transplantation for immune system reconstitution before
orthotopic implantation of EO771 tumor cells. This resulted in reduced EO771 tumor
growth and tumor weight at sacrifice after 35 days of tumor growth (Figure 4.2B). There
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was little difference between the average spleen weights between the two groups (Figure
4.2C). However, it was found that both spleens and tumor-draining lymph nodes
contained significantly more cells in the miR155tg bone marrow transplant recipient
(BM-miR155tg) mice (Figure 4.2D). These data suggest that there was likely a more
robust antitumor immune response in the BM-miR155tg mice, both locally and, to some
degree, systemically. The final gross phenotypic observation in this study was the
difference in metastatic dissemination. Lung metastases were drastically reduced in
overall burden (metastasis index = metastasis volume/total lung volume) (Figure 4.2E).
The average number of metastases was lower, but did not reach statistical significance,
though the average size of each metastasis was decreased in the BM-miR155tg recipient
mice (Figure 4.2E). Taken together, these results indicate that bone marrow miR155
overexpression resulted in a stronger antitumor immune response against orthotopic
breast tumors.
Further analysis of the immune response in the tumor microenvironment as well
as in other tissues relevant to the development of local and systemic antitumor immunity
is necessary to determine the impact of bone marrow-derived cell miR155
overexpression. Bone marrow was also collected from the right femur and tibia of every
mouse in this experiment in order to roughly determine the efficacy of the transplant.
qPCR showed that miR155 expression was on average ~10-fold higher in the
miR155tgBMT mice than those that received wild-type bone marrow, though there was
some variability (Figure 4.2F). Interestingly, though the number of bone marrow cells
collected from each mouse was not counted, we found that the total amount of mRNA
collected from the BM-miR155tg mice bone marrow was significantly higher than that of
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the BM-wild-type mice (Figure 4.2G). This most likely indicates that more bone marrow
cells were present in the BM-miR155tg mice, though the same number of cells were
originally transplanted into each mouse. It is likely that the miR155 imparts some
increased proliferative capacity to these progenitor cells [189].
Bone marrow cell miR155 overexpression increases dendritic cell frequency, maturation,
and T cell activation in tumor tissue and tumor draining lymph nodes
Based on results previously reported by our lab and others, the observed
differences in EO771 tumor progression between BM-miR155tg and BM-wild-type mice
may be due to the activities of any number of immune cell populations. Our previous
studies using total body miR155-/- mice indicated that, of the immune cell types analyzed
in tumor draining lymph nodes (B cells, T cells, macrophages, and DCs), DCs were most
significantly decreased in number, and likely contribute to the observed T and B cell
deficits in addition to the miR155-/- in both of these cell types. In order to generate a more
complete picture of the role of miR155 in the immune response to breast cancer, we
investigated several immune cell populations in the tumors, tumor-draining lymph nodes,
spleens, and blood of BM-miR155tg and BM-wild-type mice. These tissues were chosen
to collectively represent both systemic and local tumor immunity, and determine the
effect of miR155 overexpression on the balance between antitumor immunity and tumorinduced immune suppression.
In the blood, it was found that there was no difference in total T cell percentage,
but there were more CD8+ T cells and less CD4+ T cells in the BM-miR155tg mice
(Figure 4.3A). CD69 staining was used to determine the activation of circulating T cells.
Interestingly, there were no differences in the percentages of CD69+ cells among either
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the CD4+ or CD8+ T cells, though as a percentage of total circulating T cells, there were
more CD8+CD69+ and less CD4+CD69+ cells in the BM-miR155tg mice due to the
aforementioned differences in CD4+ and CD8+ T cell populations (Figure 4.3B). The
percentage of Ly6C+ blood monocytes was not different between the two groups, and
neither was the overall presence of CX3CR1 or CCR2 on these Ly6C+ monocytes
different between the two groups Figure 4.3C). These markers have been shown to
identify monocytes preferentially infiltrating non-inflamed and inflamed sites,
respectively [190-192].
Spleen tissue was mechanically dissociated and processed for flow cytometry.
When total numbers of cells were considered, there were more CD11c+ DCs present in
the spleens of BM-miR155tg mice (Figure 4.3D). Of the maturation markers MHCII,
CD40, CD80, and CD86, all exhibited slightly higher expression on the splenic DCs of
the BM-miR155tg mice (Figure 4.3E). The overall percentages of T and B cells
(identified using CD3 and CD19, respectively) were not different between the BMmiR155tg and BM-wild-type mice, but the percentage of splenic CD8+ T cells also
expressing IFNγ was significantly higher in the miR155tgBMT mice (Figure 4.3F&G).
Taken together, these blood and spleen flow cytometry data indicate that there is a mild
systemic increase in cytotoxic adaptive immunity. The splenic DCs, while present in
greater numbers, do not appear to be drastically more activated in the BM-miR155tg
mice. The examination of relative B cell burden was meant to address concerns that
miR155 has been observed to be overexpressed in B cell lymphomas and is thought to be
causative in some cases. In fact, B cell-specific miR155 overexpression in mice has been
observed to result in B cell lymphoma formation, though we observed no aberrant
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relative expansion of B cells when miR155 was overexpressed in our bone marrow
transplant model. This could be due to the adult bone marrow contributing more to
myeloid than lymphoid populations.
Tumor draining lymph nodes were also analyzed by flow cytometry and were
found to contain many more CD11c+ DCs in the BM-miR155tg mice, and these DCs also
expressed much higher levels of the maturation marker CD80. CD40, MHCII, and CD86
expression was not found to be significantly different between the two groups (Figure
4.3H&I). CCR7 expression was found to be much higher on the BM-miR155tg lymph
node DCs, a result supportive of our previous finding that miR155 indirectly upregulates
CCR7 transcription in DCs (Figure 4.3J). BM-miR155tg mouse lymph nodes also
contained slightly more CD8+ T cells, but many more of these cells expressed IFNγ than
those of BM-wild-type mice (Figure 4.3K).
Primary tumors in BM-miR155tg mice were found to contain more CD11c+ DCs
which also expressed more MHCII, CD80, and CD86 than tumor DCs from BM-wildtype mice (Figure 4.3L&M). Also the DCs in the BM-miR155tg group’s tumors again
expressed more CCR7 than those of BM-wild-type mice (Figure 4.3N). Interestingly,
significantly more macrophages (F4/80+ cells) were present in the tumors of BMmiR155tg mice, but these macrophages expressed less CD206, a marker of tumorpromoting M2-like macrophages (Figure 4.3O). Macrophage populations were not
analyzed in any of the other tissues, but these data appear to demonstrate that miR155
may also affect macrophage polarization and the innate antitumor immune response.
Though with only this one piece of data, we cannot be sure if this is a direct effect of
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elevated miR155 expression in the macrophages, or an indirect effect brought about by
the other alterations observed in the tumor microenvironment.
4.4 DISCUSSION
Previous work by our lab and others has pointed to an immune stimulatory role
for miR155, and several studies have been performed using knockout, knockdown, and
cell-specific overexpression models to demonstrate this. However, our current study is
the first time that a total-body miR155 overexpression model has been generated. The
plan for this model is to generate DCs that constitutively express higher levels of miR155
and to test their function compared to wild-type cells in response to the breast tumor
microenvironment, but it is possible that this mouse model can be used to investigate the
effects of constitutive miR155 overexpression in other immune cell types and tissues.
When generating a transgenic mouse it is important to not only determine the presence of
the transgene in the genome, but to ensure that it is expressed to a relevant degree and
that this expression occurs throughout the animal. Due to random insertion, successful
integration of the transgene into a region that is not heavily repressed can be challenging
and require a large number of attempts to insure the successful generation of a transgenic
animal [193]. In order to produce a single transgenic founder, 90 pronuclei were injected
with the transgene. We have also confirmed that the transgene is expressed in a variety of
tissues and that this expression has been maintained over five generations. The miR155
overexpression was also shown to regulate a sampling of genes, SOCS1, CEBPβ, and
CCR7 in a pattern consistent with the literature in order to further confirm that the
overexpressed microRNA was also able to carry out its biological functions. This allowed
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us to proceed with using these mice for further studies with some degree of confidence
that stable, constitutive overexpression of miR155 had been achieved.
The first study that we performed with these mice was transplantation of bone
marrow from miR155tg mice into wild-type recipient mice, followed by EO771 breast
tumor implantation. Based on previous work, this would likely affect multiple
populations of immune cells into which these bone marrow progenitors would
differentiate. Cellular components of adaptive as well as innate immunity were analyzed
in a diverse group of tissues related to the antitumor immune response. Gross assessment
of the progression of the cancer was also quantified. In the tumor, spleen, blood, and
tumor-draining lymph nodes, the most strongly affected populations of cells were the
DCs and CD8+ T cells. These two populations exhibited both increased activation and
relative abundance in response to miR155 overexpression. This finding is consistent with
a number of previously performed studies [105, 169]. Interestingly, in the tissues
analyzed, there did not appear to be a relative expansion of B cells, pathological or
otherwise, as had been observed by others in models of B cell-specific miR155
overexpression. The development of B cell lymphoma was reported to progress as the
mice aged. We have not observed this phenomenon in the miR155tg mouse line even at
relatively advanced ages of greater than 18 months.
Increased DC and cytotoxic T cell activation, as well as the observed decrease in
the pro-tumor tumor-associated macrophage (TAM) phenotype likely all play roles in the
observed inhibition of primary tumor growth and metastatic dissemination in the BMmiR155tg mice. The reduction in metastasis was particularly striking and is the more
clinically relevant of the two measures of breast cancer progression monitored in this
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experiment. Through these experiments we have generated and validated a murine model
of global miR155 overexpression, and can now move forward with studies of specific
immune cell types, and their impacts on breast cancer progression.
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Table 4.1 Antibodies for flow cytometry
Antibody
CD45 (PE/Cy7)
CD3 (APC/Cy7)
CD4 (APC)
CD8 (FITC)
CD69 (PE)
Ly6C (PE)
CX3CR1 (FITC)
CCR2 (PE)
CD11c (APC)
CD11c (FITC)
I-A/I-E (APC/Cy7)
CD40 (PE)
CD80 (FITC)
CD86 (APC)
CD19 (PE)
IFNγ (PE)
CCR7 (PE)
F4/80 (PE)
CD206 (APC)

Product #
103113
100221
100411
100803
104507
128007
149019
150609
117309
117305
107627
124609
104705
105011
152407
505807
120105
123109
141707

Company
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

Table 4.2 Primers for RT-qPCR
Primer
U6
miR155
Primer
18s
CCR7
SOCS1
CEBPβ

Product #
MS00014000
MS00001701
Forward
CGCGTTTCTATTTTGTTGGT
GCTTCTGCCAAGATGAGGTC
TTAACCCGGTACTCCGTGAC
CAAGCTGAGCGACGAGTACA
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Company
Qiagen
Qiagen
Reverse
AGTCGGCATCGTTTATGGTC
CCACGAAGCAGATGACAGAA
GAGGTCTCCAGCCAGAAGTG
AGCTGCTCCACCTTCTTCTG

Figure 4.1 The miR155-containing transgene is present, expressed, and functional in
one founder line. A, miR155 qPCR results from 4 wild-type control and all F1 miR155tg
mice from the viable line determined to carry the transgene; all mice were tested at 4
weeks old. B-D, miR155 expression in ear tissue, macrophages, and DCs of 5 wild-type
vs. one miR155tg mouse at 4 weeks of age. E, The differential expression of genes
known to be influenced by miR155 between wild-type and miR155tg mice determined by
qPCR. . Results are shown as means ± SE (n=1-5). *p<0.05.
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Figure 4.2 Total immune system miR155 overexpression reduces breast tumor
growth and lung metastatic burden. A, Timeline of this experiment. 7 week-old, female
C57Bl/6 mice received oral antibiotics for 2 weeks both prior to and after irradiation and
bone marrow transplantation with either wild-type or miR155tg bone marrow. 4 weeks
after bone marrow transplant, 2x105 EO771 tumor cells were implanted into each of the
4th pair of mammary fat pads. B, Tumor growth over 35 days and tumor weights at
sacrifice. C, Spleen weights at sacrifice. D, Total cells in spleens and tumor-draining
lymph nodes. E, Manual counting of lung surface metastases; lung metastatic index,
number, and average size determined from serial lung sections. F, miR155 expression in
bone marrow of all mice at the conclusion of the study to confirm successful bone
marrow transplant. G, RNA quantities obtained from right femurs and tibiae of all mice.
Results are shown as means ± SE (n=10). *p<0.05, **p<0.01, ***p<0.005.
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Figure 4.3 Total immune system miR155 overexpression increases dendritic cell
frequency, maturation, and T cell activation in tumor tissue and tumor draining
lymph nodes. Blood cells were stained with CD3, CD8, CD4, CD69, Ly6C, CXC3CR1,
and CCR2 antibodies and analyzed using flow cytometry. A, Total circulating T cells
(CD3+) and relative percentages of CD4+ and CD8+ cells within this population. B, CD69
expression on CD8+ and CD4+ T cells was used to identify activated T cells. C,
Circulating monocytes were identified using Ly6C, and CXC3CR1+ and CCR2+
populations of monocytes were quantified. Spleen tissue was dissociated to a single-cell
suspension; stained with CD11c, MHCII, CD40, CD80, CD86, CD19, CD3, CD8, and
IFNγ antibodies; and analyzed using flow cytometry. D, Splenic DCs (CD11c+). E,
Splenic DC maturation was determined by MHCII, CD40, CD80, and CD86 staining. F,
Splenic B cells (CD19+). G, Total splenic T cells (CD3+) and active cytotoxic T cells
(CD8+IFNγ+). Tumor-draining lymph nodes were dissociated to a single-cell suspension;
stained with CD11c, MHCII, CD40, CD80, CD86, CCR7, CD3, CD8, and IFNγ
antibodies; and analyzed using flow cytometry. H, Lymph node DCs (CD11c+). I, Lymph
node DC maturation was determined by MHCII, CD40, CD80, and CD86 staining. J,
CCR7 expression on DCs. K, Total lymph node T cells (CD3+) and active cytotoxic T
cells (CD8+IFNγ+). Tumor tissue was digested to a single cell suspension; stained with
CD11c, MHCII, CD40, CD80, CD86, CCR7, F4/80, and CD206 antibodies; and analyzed
using flow cytometry. L, Tumor DCs (CD11c+). M, Tumor DC maturation was
determined by MHCII, CD40, CD80, and CD86 staining. N, CCR7 expression on DCs.
O, Total tumor macrophages (F4/80+), M2-like macrophages (F4/80+CD206hi). Results
are shown as means ± SE (n=10). *p<0.05, **p<0.01, ***p<0.005.
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CHAPTER 5
MIR155 OVEREXPRESSION BOOSTS DENDRITIC CELL VACCINE
EFFICACY FOR BREAST CANCER
5.1 BACKGROUND
DCs take up, process and present antigen to adaptive immune cells to foster an
effective tumoricidal response [194-196]. In fact they are considered the most effective
antigen presenting cells (APCs) [197]. It is for this reason that DCs are considered a
bridge between innate and adaptive immunity and are key to eliciting an effective T cell
response [198]. However, the immunosuppressive tumor microenvironment often renders
DCs dysfunctional [194, 199-202]. This is one of the most important mechanisms of
tumor escape from immune surveillance [203-205]. Considerable effort has been put into
developing therapies targeting or consisting of DCs to attempt to overcome or circumvent
this immune suppression, respectively [206]. One of the strategies to circumvent this
tumor-induced immune suppression is to take the patient’s own precursor cells, often
peripheral blood monocytes, and generate DCs from these for ex vivo manipulation [207].
These cells are pulsed with tumor peptide, then often treated with activating agents such
as TLR ligands or TNF-α to increase their immune stimulatory capacity [208]. This
artificial maturation and antigen acquisition process helps to focus the DCs’ activity on
the tumor while removing them from the immune suppressive environment of the tumoraffected tissue. Clinical success of these vaccines, however, has been limited for a
number of reasons, including the lack of appropriate antigens, treatment of only high
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stage disease, and re-introduction of these DCs into an immune suppressive environment
[209]. Further enhancement of antigen presentation through regulatory manipulation may
prove to be clinically valuable and help to overcome the immune suppression of the
environment into which the DCs are introduced.
It is known that several targets of microRNA-155 are downregulated in order to
facilitate adequate expression of MHCII and costimulatory molecules on DCs [184-186].
Our lab has identified microRNA-155 (miR155) as a key regulator of DC function
through studies involving miR155-/- mice and virally-induced DC overexpression in
orthotopic models of breast cancer [105]. These studies showed that a lack of miR155
results in defective antigen presentation and dampened costimulatory molecule
expression, and as a result, reduced T cell activation. It was also determined that miR155
exhibits control over CCR7 expression by decreasing H3K27me3 at the CCR7 locus
through direct targeting of Jarid2. In order to test the potential therapeutic ramifications
of increased miR155 expression in DCs for breast cancer treatment, a robust model of
miR155 transgenic overexpression was generated, and cells from these mice were used to
demonstrate the effects of increasing DC miR155 expression on antitumor immunity in a
murine model of breast cancer. The goals of this study were to investigate the phenotypic
changes resulting from miR155 overexpression in DCs and to test the efficacy of a
miR155-overexpressing DC vaccine for breast cancer.
5.2 DETAILED METHODS
Tumor cell culture, conditioned medium, and lysate collection
EO771 tumor cells were expanded in high-glucose Dulbecco’s modified eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL
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penicillin (Sigma-Aldrich Corp.), and 100 µg/mL streptomycin (Sigma-Aldrich Corp.) in
a 37˚C, humidified, 5% CO2 incubator. Tumor conditioned medium was collected by first
expanding EO771 cells to 70% confluence for in T-75 bottles (Corning). Medium was
then removed, plates were gently rinsed once with phosphate-buffered saline (PBS), and
10 mL of serum-free DMEM containing penicillin and streptomycin (P/S) was added.
Cells were cultured for 48 h in this medium, which was then collected, centrifuged at 350
x g for 5 min to remove large cellular debris, and filtered through a 45-µm vacuum filter
(Corning). This medium was then concentrated using 3000D molecular weight cutoff
centrifuge concentrators (Merck Millipore, Burlington, MA) to 25X. Aliquots were
stored at -80˚C for later use. To treat immature DCs, conditioned medium was diluted 1:5
in fresh RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 100 U/mL
penicillin (Sigma-Aldrich Corp.), 100 µg/mL streptomycin (Sigma-Aldrich Corp.), and
50 µM beta mercaptoethanol.
Tumor cell lysate for DC antigen loading was obtained by culturing EO771 cells
in 10 cm cell culture-treated plates to 70% confluency in DMEM+10% FBS+P/S. About
30 plates of cells were processed for each batch of lysate. In preparation for lysate
collection, plates were washed with PBS, then replenished with 10 mL serum-free
DMEM and cultured for 48 h in a humidified, 5% CO2 atmosphere. At the end of this
incubation period, EO771 cells were rinsed with PBS and removed from plates using 5
mL of 3-mM EDTA in PBS for 10 min at RT. Cells were pelleted by centrifugation,
rinsed with PBS, and again pelleted. The cell pellet was then subjected to four
freeze/thaw cycles alternating from 5 min in liquid nitrogen to 15 min in a 37˚C water
bath. After the final freeze/thaw cycle, the pellet was vigorously resuspended in 5 mL
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PBS, then centrifuged at 1x104 g for 10 min to remove cell fragments. The supernatant
was collected and protein concentration was determined using the Lowry method. Singleuse aliquots of known protein concentration were stored at -80˚C. This material was used
as a source of soluble tumor antigen.
Bone marrow-derived dendritic cell differentiation and antigen pulsing
Entire hind limbs were removed from mice and dipped in 70% ethanol then
placed in ice-cold PBS. Femurs and tibiae were cleaned on ice in a laminar flow hood.
Sterile mortar and pestle (Thermo Fisher Scientific) were used to crush bones in 4 mL
RPMI-1640 medium+10% heat-inactivated FBS+P/S+BME (complete RPMI). Crushed
bone fragments were rinsed with complete RPMI until all bone marrow was removed and
collected. Bone marrow was depleted of erythrocytes using 1 mL red blood cell lysing
buffer (Sigma-Aldrich Corp.) for 1 min with gentle pipetting at RT. The resulting cells
were counted and cultured in 10cm cell culture-treated dishes at a density of 1x106
cells/mL (10 mL per dish) in complete RPMI supplemented with 20 ng/mL recombinant
GM-CSF (rGM-CSF) and 20 ng/mL rIL-4 (Peprotech) in a 37˚C, humidified incubator.
10 mL fresh complete RPMI supplemented in the same way was added on Day 3 of
culture. After eight days of culture, loosely adherent cells were collected by gentle
pipetting. Cells were confirmed >80% CD11c+, >90% CD11b+, and <5% Gr1+. These
resulting cells were suspended in either control or treatment medium at densities ranging
from 0.2x106 cells/mL to 1x106 cells/mL for various experiments, then cultured for 48 h.
Control medium consisted of complete RPMI+20% serum-free DMEM. Treatment
medium was made up of complete RPMI+20% concentrated EO771-conditioned
medium+100 µg/mL tumor lysate. After this tumor antigen pulsing treatment, DCs were
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collected using 3-mM EDTA in PBS for 10 min at RT, washed, and used for various
purposes.
In vitro dendritic cell migration assay
100 ng/mL CCL19 (Biolegend) in serum-free RPMI-1640 medium was added to
24 well plates and allowed to equilibrate overnight in a 37˚C humidified, 5% CO2
incubator. 0.2x106 control and tumor antigen-pulsed DCs were seeded into 8-µm pore
size polystyrene trans-well inserts (Corning) in serum-free RPMI-1640 and allowed to
migrate for 3 h at 37˚C. Trans-well inserts were then removed from these inserts and
fixed in 4% paraformaldehyde for 20 min on ice. Cells on the upper surface of the inserts
were wiped away with cotton swabs. Cells that had migrated to the underside of the insert
were be stained with DAPI and counted. Each sample was run in triplicate, and 10 fields
were collected at 10X magnification for each membrane using an EVOS FL Auto 2
System. DAPI-stained cells were counted in each field using Image-Pro Plus analysis
software (Media Cybernetics, Rockville, MD).
In vivo dendritic cell migration assay
Female C57BL/6 mice were housed at the University of South Carolina Animal
Research Facility until they were 8 weeks old; all procedures were approved by the
Institutional Animal Care and Use Committee. 0.2x106 EO771 tumor cells suspended in
20 µL PBS were implanted into the 4th pair of mammary fat pads. The following day
control and tumor antigen-pulsed DCs, treated as described, were stained with CFSE
(Biolegend) per the manufacturer’s protocol and injected subcutaneously into the groins
of tumor-bearing mice. 48 h later, mice were sacrificed, lymph nodes were removed and
processed for flow cytometry to identify CFSE-labeled cells.
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In vitro T cell activation and proliferation
Day 8 bone marrow-derived DCs were plated in 24-well plates at a density of
0.1x106 cells in 0.5 mL of either control or treatment medium and cultured for 48 h in a
37˚C, 5% CO2, humidified incubator. T cells were obtained from the spleens of C57BL/6
wild-type mice 12-20 weeks of age. This involved mechanical dissociation using a
Seward Stomacher followed by passage through a 70-µm cell strainer (Corning) and
treatment with 3 mL red blood cell lysing buffer for 1 min at RT. T cells were isolated
from mixed splenocytes using EasySepTM Mouse T cell Isolation Kits (Stem Cell
Technologies, Vancouver, Canada). Isolated T cells were then co-cultured with DCs to
assess DC-induced naïve T cell activation and proliferation.
To assess DC-induced T cell activation, DCs were rinsed with PBS very gently
twice to remove residual treatment medium, then 1-2x106 splenic naïve T cells were
added in 1 mL complete RPMI-1640 medium. The co-culture was maintained in a 37˚C,
5% CO2, humidified incubator for 48 h, then T cells were collected by rinsing the wells
and stained to determine cell surface expression of CD69 on all T cells and intracellular
expression of IFNγ on CD8+ T cells for flow cytometry.
T cell proliferation was determined by staining naïve splenic T cells with CFSE,
then co-culturing these cells with matured DCs for 5 days in complete RPMI-1640
medium supplemented with 20 U/mL recombinant mouse IL-2 (Biolegend). CFSE
dilution through division was determined by flow cytometry. CFSE-stained samples of T
cells alone and unstained T cells were used as representative negative and positive
proliferation controls, respectively.
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In vivo T cell activation
7 week-old, female C57BL/6 mice were housed at the University of South
Carolina Animal Research Facility; all procedures were approved by the Institutional
Animal Care and Use Committee. At 8 weeks of age, 0.2x106 EO771 breast tumor cells
were implanted into each of the 4th pair of mammary fat pads in all mice. 24 h after tumor
implantation, EO771 tumor-conditioned medium and lysate-matured wild-type or
miR155tg bone marrow-derived DCs were collected and 1x106 cells were injected
subcutaneously into the groins of tumor-bearing mice (0.5x106 DCs injected into the left
groin area, and the same for the right). A second DC injection was administered in the
same manner four days later. Mice were sacrificed seven days after tumor cell
implantation. Spleens and lymph nodes were collected and processed for flow cytometric
analysis of T cell activation and a few other immunologically relevant parameters.
Tumor model and dendritic cell vaccination
Female C57BL/6 mice were purchased at 7 weeks of age (Jackson Labs) and
housed at the University of South Carolina Animal Research Facility; all procedures were
approved by the Institutional Animal Care and Use Committee. At 8 weeks old, 0.2x106
EO771 breast tumor cells suspended in 20 µL PBS were implanted into the 4th pair of
mammary fat pads in all mice. 24 h after tumor implantation, EO771 tumor-conditioned
medium and lysate-matured wild-type or miR155tg bone marrow-derived DCs were
removed from culture dishes by incubating in 3-mM EDTA for 10 min at RT. These DCs
were then resuspended in PBS and 1x106 cells were injected subcutaneously into the
groins of tumor-bearing mice (0.5x106 DCs injected into the left groin area, and the same
for the right). This DC harvesting and injection procedure was repeated every three to
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four days for a total of six DC injections. Tumor volume was monitored until sacrifice
and was calculated according to the following formula: (short axis)2 x (long axis)/2 ≈
volume. Mice were sacrificed 38 days after tumor cell implantation (19 days after the
final vaccine injection). Tumors, tumor-draining lymph nodes, spleens, and lungs were
collected for various analyses.
Flow cytometry
Several tissues were collected and dissociated into single cell suspensions for
flow cytometric analysis. Blood was collected in 1.5 mL Eppendorf tubes containing 10
µL 0.5-M EDTA as an anticoagulant. 100 µL of this mixture was then treated with 3 mL
red blood cell lysing buffer for 1 min at RT with gentle pipetting, rinsed counted, and
1x106 cells were suspended in 100 µL PBS for staining. Blood cells were blocked with
anti-CD16/32 antibodies as described and stained with the following markers for 30 min
at 4˚C: anti-CD45 PE-Cy7, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD8 FITC, antiCD69 PE, anti-Ly6C APC, anti-CCR2 PE, and anti-CX3CR1 FITC.
Spleens were mechanically dissociated using a Seward Stomacher in 10 mL
RPMI-1640 medium supplemented with P/S. This mixture was then passed through a 70µm cell strainer (Corning) and treated for 1 min at RT with 3 mL red blood cell lysing
buffer (Sigma-Aldrich Corp.), rinsed with PBS, counted, and 1x106 cells were suspended
in 100 µL PBS for staining. Splenocytes were blocked with anti-CD16/32 antibodies as
described and stained with the following markers for 30 min at 4˚C: anti-CD45 PE-Cy7,
anti-CD11c APC, anti-CD11c FITC, anti-CD3 APC-Cy7, anti-CD19-APC, anti-CD4
APC, anti-CD8 FITC, anti-IFNγ PE, anti-CD40 PE, anti-IA/IE(MHCII) APC-Cy7, antiCD80 FITC, anti-CD86 PE.
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Lymph node cells were dissociated using 70-µm cell strainers (Corning), rinsed,
counted, and 1x106 cells were suspended in 100 µL PBS for staining. Lymph node cells
were blocked with anti-CD16/32 antibodies as described and surface stained with the
following markers for 30 min at 4˚C: anti-CD45 PE-Cy7, anti-CD11c APC, anti-CD11c
FITC, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD8 FITC, anti-CD69 PE, anti-CD40
PE, anti-CD80 FITC, anti-CD86 PE, anti-IA/IE(MHCII) APC-Cy7, anti-CCR7 PE, antiF4/80 PE, and anti-CD206 APC. Internal staining was performed using a BD
Cytofix/Cytoperm Fixation Permeabilization Kit (BD Biosciences) according to the
manufacturer’s instructions. The antibodies used to stain intracellular antigens were antiIFNγ PE and anti-FOXP3 PE, each at a concentration of 4 µg/mL in the specified buffer.
Tumor tissue was chopped into <1 mm3 fragments and enzymatically digested in
the following mixture: 20 mg Collagenase IV (Worthington Biochemical Corporation,
Lakewood, NJ), 10 µg Hyaluronidase (Sigma-Aldrich Corp.), and 100 µg DNase 1
(Sigma-Aldrich Corp.) in 5 mL RPMI-1640 medium supplemented with P/S. Digestion
took place in a 37˚C water bath for 1 h during. During this time, the mixture was agitated
every 15 min by pipetting or vigorous shaking. The mixture was then further disrupted
using an 18 gage needle and 10 mL syringe until most visible fragments were broken up.
The mixture was then placed back at 37˚C for 15 more min of digestion. After this final
incubation, add 20 mL RT or ice-cold PBS to each tube to stop digestion. Cells were
thoroughly rinsed to remove all digestion enzyme. Red blood cells were lysed using RBC
lysing buffer (Sigma-Aldrich Corp.), 3 mL for 1 min at RT with gentle pipetting. This
was then diluted with 20 mL PBS and passed through a 70-µm strainer, then suspended
in PBS and counted. Lymph nodes and spleens were mechanically dissociated and passed
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through a 70-µm strainer. Spleen cells were then treated with 1 mL RBC lysing buffer for
1 min at RT with gentle pipetting. Both splenocytes and lymphocytes were then rinsed,
resuspended in PBS and counted. Blood was collected in 1.5 mL Eppendorf tubes
containing 12 µL 0.5-M EDTA to prevent clotting. 100 µL of each blood sample was
collected for treatment with 1 mL RBC lysing buffer as described previously, rinsed with
PBS and counted.
All samples were washed twice with PBS after staining and resuspended in 500
µL PBS for flow cytometry. Samples were analyzed on a BD FACS Aria II using FACS
Diva software (BD Biosciences). 100,000 events were collected for each sample. All
antibodies mentioned here were purchased from Biolegend.
Total RNA extraction and quantitative real-time PCR
Tissue/cells were lysed in 700 µL qiazol lysis reagent (Qiagen) and tissue samples
were homogenized. Samples were stored at -80˚C if RNA extraction was not performed
immediately. RNA was extracted using Qiagen miRNeasy Mini Kits to also ensure
collection of micro-RNAs. cDNA was then synthesized using 1 µg RNA, or the
maximum amount possible if less than 1 µg, using Qiagen miScript II RT kits. Primers
are listed in table 5.1. qPCR run conditions were 95˚C for 15 min followed by a repeated
cycling of 94˚C for 15 s, 55˚C for 30 sec, and 70˚C for 30 s. A melt curve was then
collected through the following temperature fluctuations: 95˚C for 10 s, 65˚C for 5 s, and
terminating again at 95˚C. All samples were run in duplicate using a Bio-Rad CFX Real
Time thermocycler. The ΔΔCt method was used to determine relative expression.
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Metastasis quantification
Following PFA fixation for 24-48 h at RT, mouse lungs were paraffin imbedded
and sections were cut 5 µm thick at 150 µm intervals. Five such sections were obtained
for each lung pair. These were deparaffinized and stained with hematoxylin and eosin.
Stained slides were imaged at 10X magnification using an EVOS FL Auto 2 System
(Thermo Fisher Scientific). Images were tiled in order to view the entire lung using the
EVOS System software. Size of images were limited such that they did not require
compression to be saved by the EVOS System software, ensuring that pixels represented
equivalent real dimensions on every section. Pixel areas of lung tissue and metastases
were measured for each image by hand using ImageJ software. These pixel values were
converted to mm2 using the conversion factor 1.142 pixels/µm determined by the 10X
objective. The number of metastatic nodules per section was also counted. These values
were used to calculate the following parameters for each lung pair: 1) metastatic burden =
(metastatic volume)/(total lung volume), 2) (number of metastases per section)/(lung
section area).
Statistical analysis
Data were shown as mean ± standard error of mean (SEM) whenever the mean
was the primary value representative of a sample group’s behavior. Three group
comparison of means is accomplished using a two tailed ANOVA followed by Tukey
multiple comparisons test, while two group comparison was accomplished using a two
tailed Student’s t test. All such comparisons are performed using GraphPad Prism 5
software (Graphpad Software Inc.). Differences between proportions were determined
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using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for
all tests.
5.3 RESULTS
Dendritic cell maturation is increased by miR155 overexpression
DCs constantly sample their environments, take up antigen, and mature. This
maturation process involves the up-regulation of MHCII, on which antigen is presented,
as well as co-stimulatory molecules such as CD40, CD80, and CD86. Upon interaction
with the corresponding stimulatory surface receptors of T cells, including CD40 ligand
(CD154), T cell receptor, and CD28, T cell activation is induced. DC maturation is also
accompanied by an increase in CCR7 expression, which enables DCs to respond to
chemoattractant molecules such as CCL19 and CCL20 and migrate to draining lymph
nodes where their chance of interacting with a receptive T cell is greater. Our previous
results in miR155-/- mice showed that all of these molecules associated with DC
maturation and migration were decreased compared to wild-type in response to tumor
material, and their induction of a T cell response was much weaker. For our desired
therapeutic outcome of increasing dendritic cell-mediated antitumor immunity,
augmented miR155 expression is the goal. Thus a total body transgenic model of miR155
overexpression was generated on a C57BL/6 background and was confirmed to express
increased levels of functional miR155. Bone marrow cells from these transgenic mice
(miR155tg) and wild-type mice were harvested and differentiated into DCs by treating
with GM-CSF and IL-4 for 8 days. At the end of this differentiation period, flow
cytometry confirmed that >80% of the cells were CD11c+, >95% of the cells were
CD11b+, and <5% of the cells were Gr1+ (Figure 5.1A). These cells were considered
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immature DCs. In order to mature them and gage the effects of their exposure to tumor
antigen, immature wild-type and miR155tg DCs were each divided into two groups. One
of which was treated with EO771 tumor-conditioned medium (ECM) and EO771 tumor
cell lysate, the other was treated only with the corresponding medium as a control. Our
results show that miR155tg DCs pulsed with tumor material in this way exhibit higher
expression of MHCII, CD80, and CD86 than wild-type cells (Figure 5.1B). Interestingly,
CD40 appeared to be expressed at a lower level in miR155tg DCs. CCR7 expression,
which our lab has shown is linked to miR155, is drastically increased in both tumor
antigen-pulsed and naïve miR155tg DCs (Figure 5.1C). Overall, these results point to a
likely increase in miR155tg DCs’ capacity to both reach lymph nodes, and once there to
activate T cells. In vivo assessment of DC maturation in the spleens, lymph nodes, and
tumors of mice transplanted with either miR155tg or wild-type bone marrow yielded
similar results (Figure 4.3). Thus over-expression of miR155 in DCs does appear to
increase maturation upon exposure to breast cancer antigens both in vitro and in vivo.
miR155tg dendritic cells exhibit increased migration in vitro and in vivo
The observation of increased CCR7 expression on miR155tg DCs is a strong
indication that their migratory ability may be increased. A trans-well migration assay was
performed using a gradient of CCL19 on control and tumor-pulsed wild-type and
miR155tg DCs. Wells containing no CCL19 were used to gage the baseline levels of
migration for each genotype and treatment condition. The results of this in vitro
experiment mirrored the CCR7 expression results (Figures 5.2A). Transgenic DCs
migrated to a much greater extent than wild-type under both treatment conditions. In fact,
the migration of control-treated miR155tg DCs was greater than wild-type cells pulsed
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with tumor antigen. Interestingly, miR155tg DCs exhibited less baseline, random
migration but were much more responsive to CCL19 (Figure 5.2B).
In vivo DC migration was also tested by introducing wild-type and miR155tg
tumor antigen-pulsed DCs, which had been labeled with CFSE dye, into the groins of
wild-type mice bearing EO771 tumors. DCs were given two days to migrate, at which
time the draining lymph nodes were removed. Mice receiving no DCs served as negative
controls for identifying CFSE+ cells. Results showed that CFSE+ DCs of both genotypes
arrived at the draining lymph nodes, and there was a trend toward miR155tg DCs having
migrated to a greater extent, but the difference was not statistically significant (Figure
5.2C). The small number of mice per group (3) may have contributed to this null result.
However, taken together, these data suggest that miR155 expression levels directly
correlate with the ability of DCs to migrate in response to lymph node chemoattractants.
miR155tg dendritic cells elicit increased T cell activation in vitro and in vivo
In response to the observed increase in maturation marker expression on
miR155tg DCs, it should follow that T cell activation and proliferation would also
increase. To determine if this was indeed the case, splenic T cells from healthy, wild-type
mice were co-cultured with miR155tg and wild-type DCs pulsed with tumor antigen. By
analyzing T cell surface expression of CD69 and internal expression of IFNγ, we
determined that miR155 overexpression led to significant increases in CD4+ and CD8+ T
cell activation with IFNγ expression also increased in CD8+ T cells (Figures 5.3A&B).
T cell proliferation in response to this DC co-culture was also tested by staining
the naïve T cells with CFSE and determining the decrease in fluorescence due to division.
Our results show that T cells proliferate significantly more in response to DCs pulsed
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with tumor antigen for both genotypes, and that miR155tg DCs induce more T cell
proliferation than wild-type DCs, whether naïve or antigen pulsed (Figure 5.3C).
It is important to determine whether these T cell activation results can be
replicated in vivo for the sake of therapeutic relevance. This was done by administering
tumor antigen-pulsed wild-type and miR155tg DCs subcutaneously into the groins of
wild-type, EO771 tumor-bearing mice. CD69 expression was used to define both CD4+
and CD8+ activated T cells. T cell activation in tumors, spleens, and tumor-draining
lymph nodes was determined to be increased in mice that received miR155tg DCs
compared to wild type and no DC controls (Figures 5.3D&E). This increased activation
was present in both CD4+ and CD8+ T cells in most tissues. It was also noted that spleen
and tumor-draining lymph node cellularity was increased in mice receiving miR155tg
DCs (Figure 5.3F). Given the increased T cell activation in vivo and in vitro, this change
in the numbers of lymph node and spleen cells is likely due to an augmented antitumor
immune response initiated by the introduction of mature miR155tg DCs.
miR155tg dendritic cells reduce systemic immune suppression
Apart from assessing T cell activation, several other immune cell populations
were analyzed. These were intended to provide a broader picture of the immune
phenotype brought about by the introduction of miR155tg and wild-type DCs to tumorbearing mice. Spleen DC maturation, which was determined by MHCII expression, was
significantly higher in mice inoculated with miR155tg DCs than both wild-type DC and
no DC groups (Figure 5.4A). Tumor draining lymph node DCs also expressed more
MHCII in miR155tg vaccinated mice than wild-type or no DC control mice (Figure
5.4B). It is likely that a portion of these DCs are those that were injected, but given
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previous tracking of DCs implanted in the same way, it is more likely that the vast
majority of these cells were the mice’s own. Macrophages were more abundant in the
tumors of mice that received no DCs than either of the DC-inoculated groups (Figure
5.4C). Macrophage abundance is an important and generally negative prognostic
indicator in breast cancer [210]. There was also an abundance of myeloid-derived
suppressor cells (MDSCs) in the tumors of non-DC injected mice, here identified as
CD11b+Gr1+ (Figure 5.4D). Significant increases in these two cell populations brought
about an overall increase in tumor CD45+ cells (Figure 5.4E). These data suggest that, in
this case, only two injections of tumor antigen pulsed DCs can bring about a robust and
systemic increase in immunologic tone, and this is significantly augmented by miR155
overexpression in the implanted DCs.
miR155 overexpression increased the efficacy of a dendritic cell-based vaccine for breast
cancer
To investigate the potential therapeutic efficacy of the miR155-overexpressing
DC-based cancer immune therapy, a therapeutic vaccine strategy was implemented in
mice bearing EO771 breast tumors. These mice received tumor antigen-pulsed wild-type
or miR155tg DCs twice per week for 3 weeks. Another group of mice received injections
of only PBS on the same schedule as a vehicle control. Tumor growth was monitored
during this vaccination period and for 19 days after (Figure 5.5A). Tumor growth was
significantly inhibited in both DC vaccine groups, but miR155tg DC-vaccinated mice
exhibited more suppressed tumor growth than those receiving wild-type DC vaccination
(Figure 5.5B). It was clear from the examination of mice shortly after receiving DC
injections, that DC miR155 overexpression could induce a significant increase in T cell
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activation. In this study we wanted to see if this gain in immune function could be
maintained for a significant period after the full course of the vaccine was administered.
With the intent of such therapeutic vaccines being to boost specific and systemic
antitumor immunity, it would be advantageous for the treatment to bring about a
sustained immune response focused on the primary tumor as well as distant metastases.
At the time of sacrifice, 19 days after the administration of the last vaccine injection,
miR155tg DC-vaccinated mice exhibited lower average tumor weight than mice that had
received no DCs, while wild-type vaccinated mice did not maintain this difference
(Figure 5.5C). Tumor draining lymph node weight and cellularity were also higher in
miR155tg DC-vaccinated mice (Figure 5.5D). Cytotoxic T cells (CD8+IFNγ+) were also
more abundant in the tumors, spleens, and tumor-draining lymph nodes of miR155tg DCvaccinated mice than non-vaccinated mice (Figure 5.5E). Cytotoxic T cell frequency at
least trended higher in miR155tg DC-vaccinated mice than mice that received wild-type
DCs (Figure 5.5E). Tumor DC MHCII also remained higher in miR155tg vaccinated
mice. It is somewhat possible, but unlikely that any of these DCs were the ones
introduced in the vaccine injections after 19 days (Figure 5.5F). Taken together, these
data show that a systemic elevation in immunologic tone is maintained for an extended
period after vaccination has ended. This immune response as well as the
contemporaneous effects of the vaccine leading to decreased metastasis are important
indicators of its therapeutic potential.
5.4 DISCUSSION
Our data revealed that overexpression of miR155 in DCs increased maturation in
response to tumor-produced cytokines and antigen. CCR7 expression was also increased
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in agreement with our previous results in miR155-/- animals. This increase in CCR7
expression yielded an increase in the migratory response of DCs to CCL19, a key
cytokine produced by high endothelial venules and T cell zones in lymph nodes to attract
antigen-loaded DCs [211]. DC-induced T cell activation and proliferation were also
significantly increased by DC overexpression of miR155. The injection of miR155tg DCs
into EO771 tumor-bearing mice resulted in a more pronounced decrease in systemic
tumor-induced immune suppression than the injection of wild-type DCs. This was
observed as an increase in tumor, spleen, and tumor-draining lymph node DC activation,
as well as dramatic decreases in tumor MDSCs and macrophages. Finally,
implementation of a basic DC vaccination regimen in an orthotopic model of metastatic
murine breast cancer showed that DC miR155 overexpression was able to improve the
vaccine’s capability to slow primary tumor growth and maintain antitumor immunity
long after the last vaccine injection had been administered. Our DC vaccine regimen does
not employ any additional maturation stimulants, such as TLR4 ligands or TNF-α due to
the fact that our objective here is not to implement the maximally matured DC vaccine, it
was to study the effects of miR155 overexpression on DC maturation and resulting
antitumor immunity. Taken together, these data support the conclusion that
overexpression of miR155 significantly increases the efficacy of DC vaccines targeting
breast cancer, and that such a regulatory manipulation may improve the prospects of
developing effective DC-based immune therapies for human breast cancer.
A number of previous studies have been focused on the role of miR155 in a wide
variety of DC functions from development to apoptosis to immune activation [161, 186].
Depending on the focus of the study, miR155 has been linked to everything from
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hampering immune function to improving it to a beneficial or even pathological degree
[180, 212, 213]. Previous models of miR155 overexpression have been based on either
Cre-Lox recombination or viral overexpression. Some such models have shown that
increased DC miR155 led to increased apoptosis upon activation, though based purely on
viability we did not observe this, and even if apoptosis was increased to some degree, this
did not seem to effect the outcomes of increased T cell activation or antitumor immunity
induction [186]. Many studies, however have demonstrated that miR155 is upregulated
upon treatment with various maturation-inducing ligands, most commonly LPS [185,
186, 214]. However, some studies have reported no difference in LPS-induced DC
maturation (expression of CD40, CD80, CD86, and MHCII) when miR155 is knocked
down or even completely knocked out [161, 186]. Even without this difference in
maturation markers, impaired T cell activation was observed [185]. Our previous work
focused on inducing DC maturation using only tumor-derived material, not LPS, and we
found that lack of miR155 resulted in both significantly impaired maturation and
subsequent T cell activation as well as augmented tumor growth.
One way in which increasing DC miR155 expression has been found to have a
potentially deleterious effect on proper antigen presentation is through indirectly
decreasing the expression of the C-type lectin DC-SIGN, a molecule capable of binding
high mannose-containing glycoproteins present on viruses, bacteria, fungi, and tumor
cells [212, 215-217]. It has been shown that APCs such as DCs interact with tumor
glycoproteins such as MUC-1 [215]. The status of DC-SIGN as a Pattern-Associated
Molecular Pattern receptor (PAMP) has also led to its targeting in some cocktails
intended to stimulate DCs for therapeutic and preventative vaccination [218-222]. This
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decrease in DC-SIGN expression occurs physiologically over the course of DC
maturation, during which antigen uptake decreases and mir155 expression increases
[212]. However, our results show that DC-SIGN is actually expressed to a higher degree
on miR155tg DCs than wild-type (Figure 5.6A), and the net effects of increasing DC
miR155 generally increased the ability of DCs to foster an antitumor immune response. It
has even been shown that miR155 suppresses IL-1 expression in DCs during maturation
[180]. It is possible that this is to prevent potentially damaging level of inflammatory
cytokine production while still inducing an effective immune response. Our data show
that miR155tg DCs do indeed express much less IL-1β in response to tumor material than
wild-type DCs (Figure 5.6B).
Overall, the balance between immune activation and suppression by miR155 was
tipped in the direction of increased DC maturation and T cell activation due to its
multiple directly immune stimulatory effects, some of which we have confirmed in our
model. Suppressor of cytokine signaling 1 (SOCS-1) is a direct target of miR155 and has
been shown to regulate the production of IL-12, a key cytokine necessary for the
complete activation of T cells and other immune cells with which DCs interact [186].
Overexpression of miR155 in DCs increased IL-12p70 expression, and thus increased
IFNγ production in co-cultured NK cells [186]. We found that SOCS-1 expression was
decreased in our miR155tg DCs, consistent with these previous results (Figure 4.1E),
and that IL-12β subunit expression was increased compared to wild-type DCs upon
tumor exposure (Figure 5.6B). The transcription factor component c-Fos has also been
shown to be a direct target of miR155 in DCs [185]. Transcription factor complexes
containing c-Fos were shown to suppress DC maturation, thus miR155 blocks this
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suppression and facilitates DC activation. Our miR155tg DCs also exhibited decreased cFos expression and increased maturation in response to tumor material (Figure 5.6B).
Though there is still debate regarding the complex roles of miR155 in DC
development, maturation, and immune activation, it is clear that miR155 is an important
regulator of DC biology. It has been shown that miR155 directly influences a network of
other microRNAs in DCs in addition to the many functions described previously [223]. In
our model of miR155 transgenic overexpression, the net result was increased DC
maturation, T cell activation and proliferation, and increased migration in response to
lymph node chemoattractants. Use of these DCs in a breast cancer therapeutic
vaccination resulted in decreased tumor growth and tumor-induced immune suppression.
These results, as well as the regulatory activities of miR155 described in previous
literature, suggest that forced overexpression of miR155 may enhance the therapeutic
efficacy of DC-based vaccines for solid tumors such as breast cancer.
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Table 5.1 Antibodies for flow cytometry
Antibody
CD45 (PE-Cy7)
CD11b (FITC)
CD11c (APC)
CD11c (FITC)
Gr1 (PE)
I-A/I-E (APC-Cy7)
CD40 (PE)
CD80 (FITC)
CD86 (APC)
CCR7 (PE)
CD3 (APC-Cy7)
CD4 (APC)
CD8 (FITC)
CD69 (PE)
IFNγ (PE)
F4/80 (PE)
DC-SIGN (PE)

Product #
103113
101205
117309
117305
108407
107627
124609
104705
105011
120105
100221
100411
100803
104507
505807
123109
833003

Company
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

Table 5.2 Primers for RT-qPCR
Primer
U6
miR155
Primer
18s
CCR7
IL-12β
IL-1β
cFos

Product #
MS00014000
MS00001701
Forward
CGCGTTTCTATTTTGTTGGT
GCTTCTGCCAAGATGAGGTC
GAGAAGGTCACACTGGACCA
GCCCATCCTCTGTGTGACTCAT
CTGGTGGAGATGGCTGTCAC
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Company
Qiagen
Qiagen
Reverse
AGTCGGCATCGTTTATGGTC
CCACGAAGCAGATGACAGAA
TGACCTCCACCTGTGAGTTC
AGGCCACAGGTATTTTGTCG
GGGCTCTCCTGTCAACACAC

Figure 5.1 Dendritic cell maturation is promoteded by miR155 overexpression. A,
Representative flow cytometry dot plots showing the results of bone marrow DC
differentiation with 20 ng/mL GM-CSF and 20 ng/mL IL-4. B, miR155tg and wild-type
DCs were pulsed with tumor material, stained for maturation markers (MHCII, CD40,
CD80, and CD86), and analyzed with flow cytometry. C, CCR7 epression on tumorpulsed DCs was also analyzed. Results are shown as means ± SE (n=3). *p<0.05,
**p<0.01, ***p<0.005.

144

Figure 5.2 miR155tg dendritic cells exhibit increased migration in vitro and in vivo.
A, Wild-type and miR155tg DCs were pulsed with tumor material, then exposed to a
CCL19 gradient. Migration in response to CCL19 through a trans-well insert was
quantified and representative images are shown. B, This experiment was also performed
without the CCL19 gradient. Results are shown as means ± SE (n=3). **p<0.01. C,
Migration of CFSE-stained, tumor-pulsed DCs in vivo to tumor-draining lymph nodes.
Results are shown as means ± SE (n=4).
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Figure 5.3 miR155tg dendritic cells elicit increased T cell activation in vitro and in
vivo. Wild-type and miR155tg DCs were pulsed with tumor antigen, then cocultured with naïve wild-type T cells. A and B, After 48 h of co-culture, T cells were
stained for CD3, CD4, CD8, CD69, and IFNγ, then analyzed using flow cytometry. C,
Some naïve T cells were stained with CFSE prior to co-culture; after 120 h of co-culture,
T cell CFSE fluorescence was analyzed using flow cytometry. Results are shown as
means ± SE (n=3). *p<0.05, **p<0.01, ***p<0.005. D and E, Tumor-bearing wild-type
mice were s.c. injected twice with wild-type or miR155tg tumor-pulsed DCs. Tumors,
spleens, and tumor draining lymph nodes were then harvested, dissociated to a single cell
suspension, and stained with CD45, CD3, CD4, CD8, and CD69 antibodies. Stained cells
were analyzed using flow cytometry. F, Spleen and tumor-draining lymph node
cellularity after 2 tumor pulsed DC s.c. injections. Results are shown as means ± SE
(n=6-7). *p<0.05, **p<0.01, ***p<0.005.
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Figure 5.4 miR155tg dendritic cells reduce systemic immune suppression. Tissues
collected for in vivo T cell activation analysis shown in Figure 5.4 were also stained for
other immune cell populations; spleens and lymph nodes were stained with CD11c and
MHCII antibodies; tumors were stained with CD11b, F4/80, and Gr1 antibodies. A,
Spleen DC maturation represented by the extent of MHCII staining on CD11c+ cells. B,
Lymph node DC maturation represented by the extent of MHCII staining on CD11c+
cells. C, Tumor macrophages (CD11b+F4/80+). D, Tumor MDSCs (CD11b+Gr1+). E,
Total immune cells in tumors (CD45+). Results are shown as means ± SE (n=6-7).
*p<0.05, **p<0.01, ***p<0.005.
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Figure 5.5 miR155 overexpression increased the efficacy of a dendritic cell-based
vaccine for breast cancer. A, Timeline of this experiment. 7 week-old, female C57Bl/6
mice were implanted with 2x105 EO771 cells in each of the 4th pair of mammary fat pads.
Beginning the following day and continuing for 3 weeks, mice received twice-weekly s.c.
injections of tumor-pulsed wild-type or miR155tg DCs; mice were sacrificed 38 days
after tumor implantation. B, Tumor growth. C, Tumor eight at sacrifice. D, Lymph node
weight and total cells at sacrifice. E, T cell activation in tumors, spleens and tumordraining lymph nodes was determined by staining for CD45, CD3, CD4, CD8, CD69, and
IFNγ on single cell suspensions and performing flow cytometry. F, Tumor and lymph
node dendritic cell maturation was determined by staining for CD11c and MHCII on
single cell suspensions and performing flow cytometry. G, Percentages of original 20
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mice in each group that developed tumors after EO771 cell implantation. Results are
shown as means ± SE (n=8-17). *p<0.05, **p<0.01, ***p<0.005.
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Figure 5.6 Effects of miR155 transgenic overexpression on molecules relevant to
dendritic cell function. A, Wild-type and miR155tg DCs were pulsed with EO771 tumor
lysate and conditioned medium, then stained for CD11c and CD209 (DC-SIGN) and
analyzed using flow cytometry. B, Wild-type and mir155tg DCs were treated as in A;
RNA was then extracted and qPCR performed for mir155 and genes relevant to DC
biology that have been linked to miR155 by previous studies. Results are shown as means
± SE (n=3). **p<0.01, ***p<0.005.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
The potential benefits of immune therapies for breast cancer are now beginning to
be realized for patients. Stand-alone therapies focusing on well-defined tumor antigens,
such as HER2, have been combined with more traditional therapeutic strategies such as
systemic chemotherapy, other immune stimulatory agents, and even radiation [224-226].
These combination therapies are having increased success in clinical trials and will be
important for the future of breast cancer therapy. The development and testing of new
treatments to target tumors from different angles and a comprehensive understanding of
the effects that these treatments have on the tumor itself, as well as the immune
microenvironment, are important for the design of combination therapies with additive or
synergistic effects. The major focus of cancer immune therapy has been on targeting
therapies to the tumor via unique or overexpressed antigens or increasing the activity of
adaptive immunity, specifically T cells. The two immune therapies described here focus
on macrophages and DCs in the TME. These therapies may prove to be even more
beneficial in combination with other immune or traditional therapies than on their own.
Each of these therapies will be discussed individually, then some future studies to
progress each toward clinical implementation will be discussed.
6.1 EMODIN ADJUVANT THERAPY CONCLUSIONS
Macrophages in the TME and in metastatic sites exhibit a high degree of plasticity
both over the course of cancer progression as well as in different regions of an individual
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tumor [227, 228]. During late stage disease, M2-like macrophages generally predominate,
but this activation state remains plastic and is the result of a complex network of
pathways [229, 230]. Innate immune therapies designed to address this regulatory
network must exert change while not shifting the balance too far in a pro-inflammatory
direction. Herb-derived compounds such as emodin often exert complex yet measured
effects, and thus are promising to address the TME and complement existing therapies
[231-233]. The specific mechanisms by which emodin exerts these effects are still not
known, but it has been shown to affect a number of important proteins relevant for both
inflammation and cancer including HER2/neu, NFκB, TNFα, PPARγ, IL-4, and TGF-β,
just to name a few [98, 121, 234-236]. Emodin’s effects on TGF-β signaling in a variety
of cancer cell types, including breast cancer, have been reported. Our lab, however, has
attempted to characterize emodin’s effects on macrophages in the context of breast
cancer, and has shown that it is capable of modulating macrophage M2-like polarization
[103, 118]. This resulted in reduced lung metastases as well as tumor volume. The studies
described here go further in both describing a new avenue by which emodin disrupts
macrophage-tumor cell crosstalk and demonstrating that emodin is effective as an
adjuvant chemotherapy. We show that emodin is capable of reducing macrophage TGF-β
production and reducing the effects of TGF-β (and macrophage-conditioned medium
containing secreted TGF-β) on tumor cell EMT. Such a relationship between
macrophage-secreted TGF-β and tumor cell EMT has been established in a number of
tumor models [237, 238]. As a result of these effects on tumor cells, and importantly
macrophages subjected to tumor-secreted cytokines, emodin was able to reduce
metastatic recurrence when administered as an adjuvant therapy following tumor
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resection. In this adjuvant therapy model, migratory DCs were increased and Tregs were
decreased in metastatic site-draining lymph nodes of mice treated with emodin. Both of
these components of the tumor-bearing host’s immune phenotype have been linked with
reduced TGF-β signaling. This is the first time that emodin has been shown to be an
effective adjuvant cancer immunotherapy, increasing its potential effectiveness in similar
regimens of human breast cancer treatment.
6.2 EMODIN ADJUVANT THERAPY FUTURE WORK
Though these data are promising, there are some questions that remain
unanswered which may be beneficial to address and some additional work that remains to
be done. Pertaining to the connection between adjuvant emodin therapy and increased
recurrence-free survival, while we have demonstrated a mechanistic link between the
metastatic site immune phenotype and the known effects of TGF-β, this connection
should be more firmly established. If our hypotheses are correct, knockdown of TGF-β
should diminish emodin’s effect in our orthotopic tumor resection model. This
knockdown in vivo could be achieved through crossing TGF-β-flox mice with a relatively
macrophage-specific Cre model such as the readily available LysM-cre or murine CD68cre mice, the latter of which may prove to be more specific [239]. In vitro studies
employing the addition of a TGF-β-neutralizing antibody to macrophage-conditioned
medium or non-contact co-cultures with tumor cells could demonstrate the same effect
[240].
In addition to more firmly establishing this connection, moving beyond
demonstrating broadly that emodin inhibits metastatic recurrence when treatment is
initiated after surgery and determining whether emodin has a more significant effect on
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tumor cells or cells in the lung pre-metastatic niche. This could be accomplished by
performing a group of experiments based on some form of intravenous injection of breast
cancer cells and monitoring lung metastasis formation with emodin treatment of either
tumor cells, mice prior to tumor cell implantation, or tumor-bearing mice.
An additional relationship between lung macrophages, extravasating tumor cells,
TGF-β, and emodin involves macrophage CXCR4 expression. It has been known that
perivascular macrophages play a significant role in local tumor recurrence, and that this is
at least in part due to M2-like TAMs, which express high levels of CXCR4 [241].
CXCR4 expression is also dependent on TGF-β, which is produced at relatively high
levels by tumor-exposed macrophages and tumor cells [242, 243]. CXCR4 interacts with
CXCL12, which is produced by perivascular fibroblasts at especially high levels in
metastatic sites such as lung, liver, and bone [244]. It has recently been shown that
CXCR4+ macrophages interact with motile tumor cells and facilitate their extravasation
into the surrounding tissue [242]. Given that we demonstrate here that emodin is capable
of interfering with tumor cell-macrophage TGF-β crosstalk on several levels and
reducing M2 polarization of macrophages, which is closely linked to CXCR4 expression,
it is likely that this mechanism is at play in our model of adjuvant emodin therapy to
prevent metastatic recurrence.
6.3 MIR155TG DENDRITIC CELL VACCINE CONCLUSIONS
The second immune therapy tested focuses on DCs and their potential
implementation in therapeutic vaccines for breast cancer. Though they seemed to show
great promise only recently, there have been many obstacles to the development of
effective DC vaccines. Said difficulties have often been attributed to a few crucial
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factors. First, many such therapeutic vaccine trials only involved patients with very
advanced disease. The second major issue with DC vaccines centers on the immune
suppression induced by the tumor for purposes of self-preservation. Additional and
lasting immune activation of DCs is necessary to overcome this when reintroduced into
the patient. TLR agonists such as LPS are effective maturing agents for DCs prepared ex
vivo as therapeutic vaccines. However, maturation with ligands such as these is more
vulnerable to anti-inflammatory cytokines, such as IL-10, present upon re-introduction to
the patient than strategies involving costimulatory receptor ligation or genetically forced
upregulation of maturation [245, 246]. It is for this reason that we have focused on
increasing the maturation of DCs via miR155. Our previous results have shown that
miR155 deficiency impairs DC maturation and leads to increased breast cancer
progression. The next step was to develop a stable miR155 overexpression model, then
test the effects of miR155 overexpression on DCs and use these cells in a DC therapeutic
vaccine model for breast cancer. We generated a novel, total body miR155 transgenic
overexpression mouse line and used the bone marrow from these mice for both bone
marrow transplantation and to generate DCs for in vitro testing and breast cancer
vaccination. miR155 has been shown to generally increase the activation of a variety of
pro-inflammatory immune cells while at the same time reducing the activity of
tolerogenic cell populations [247]. Bone marrow transplantation followed by orthotopic
tumor implantation allowed for the comparison of several of these cell types’ responses
between wild-type and miR155tg immune systems. The results largely pointed to an
increase in systemic immune activation, especially DC activation and presence, as well as
an increase CD8+ T cell activity. Further testing of miR155tg DCs in vitro revealed
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increased CD86, MHCII, and CD80 expression upon exposure to tumor material. Coculture of these DCs with T cells increased T cell activation and proliferation. miR155tg
DCs also exhibited higher CCR7 expression and a corresponding increase in migration in
response to CCL19. Introduction of ex vivo matured miR155tg DCs into breast tumorbearing mice reduced tumor growth and augmented antitumor immunity to a greater
extent than wild-type DCs. This effect persisted for many days after the last DC
inoculation was administered and resulted in a lower lung metastatic burden. These data
show that at least some method of delivering miR155 to DCs of immune cells more
broadly in the TME would be a beneficial strategy to pursue.
6.4 MIR155 DENDRITIC CELL VACCINE FUTURE WORK
The project focusing on the effects of miR155 in DCs and the development of a
miR155-overexpressed DC vaccine requires less additional work, but the development of
the miR155tg mouse model opens up many possibilities. Not only could a much more
detailed understanding of the regulatory changes brought about by stably increasing
miR155 expression in DCs be gained, but also in many other cell types, both immune and
otherwise. The majority of what is known about the many roles or miR155 has been
gained by making use of miR155-/- mice. Virally introduced overexpression often ends up
affecting only a small percentage of certain cells and is a more invasive method than
constitutive overexpression. This model could provide the corresponding overexpression
side to the many miR155-/- experiments, which is necessary to more firmly establish the
previously described roles of miR155 and those yet to be uncovered.
Both of these potential therapies still require further testing in order to develop
delivery methods that are more readily translatable to patients. It also may prove fruitful
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to combine these methods with other immune therapies or more traditional
chemotherapies. The added focus on treating the immune component of diseases is being
seen as more valuable, and this is particularly the case with cancers. The results of these
studies point to both emodin and miR155 as important potential additions to the
developing arsenal of immune therapies for breast cancer.
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